<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062866" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of plasma cell neoplasms (including multiple myeloma).</SummaryDescription><SummaryURL xref="http://cancer.gov/types/myeloma/hp/myeloma-treatment-pdq">Plasma Cell Neoplasms (including Multiple Myeloma)  (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000037974">multiple myeloma and other plasma cell neoplasms</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Plasma Cell Neoplasms  (Including Multiple Myeloma) Treatment  (PDQ®)</SummaryTitle><AltTitle TitleType="Navlabel">Plasma Cell Neoplasms Treatment</AltTitle><AltTitle TitleType="Short">Plasma Cell Neoplasms  (Including Multiple Myeloma) Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000037974">multiple myeloma and other plasma cell neoplasms</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Plasma Cell Neoplasms </Title><Para id="_3">There are several types of plasma cell neoplasms. These diseases are all associated with a monoclonal (or myeloma) protein (M protein). They include monoclonal gammopathy of undetermined significance (MGUS), isolated plasmacytoma of the bone, extramedullary plasmacytoma, and multiple myeloma.</Para><Para id="_312">(Refer to the   <SummaryRef href="CDR0000062707#_562" url="/types/lymphoma/hp/adult-nhl-treatment-pdq">Lymphoplasmacytic Lymphoma (Waldenström Macroglobulinemia)</SummaryRef> section in the PDQ summary on <SummaryRef href="CDR0000062707" url="/types/lymphoma/hp/adult-nhl-treatment-pdq">Adult Non-Hodgkin Lymphoma Treatment </SummaryRef> for more information.)</Para><SummarySection id="_4"><Title>Incidence and Mortality</Title><Para id="_5">Estimated new cases and deaths from multiple myeloma in the United States in 2015:<Reference refidx="1"/> </Para><ItemizedList id="_230" Style="bullet"><ListItem>New cases: 26,850.</ListItem><ListItem>Deaths:  11,240.</ListItem></ItemizedList></SummarySection><SummarySection id="_7"><Title>Clinical Presentation and Evaluation</Title><Table id="_8"><Title>Table 1.  Clinical Presentation of Plasma Cell Neoplasms</Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry>Plasma Cell Neoplasm</entry><entry>M Protein Type</entry><entry>Pathology</entry><entry>Clinical Presentation</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1">MGUS = monoclonal gammopathy of undetermined significance. </entry></Row></TFoot><TBody><Row><entry>MGUS</entry><entry>IgG kappa or lambda; 

or

IgA kappa or lambda
</entry><entry>&lt;10% plasma cells in bone marrow</entry><entry>Asymptomatic, with minimal evidence of disease (aside from the presence of an M protein) <Reference refidx="2"/></entry></Row><Row><entry>Isolated plasmacytoma of bone</entry><entry>IgG kappa or lambda; or

IgA kappa or gamma
</entry><entry>Solitary lesion of bone; &lt;10% plasma cells in marrow of uninvolved site</entry><entry>Asymptomatic or symptomatic </entry></Row><Row><entry>Extramedullary plasmacytoma</entry><entry>IgG kappa or lambda; 

or

IgA kappa or gamma</entry><entry>Solitary lesion of soft tissue; most commonly occurs in the nasopharynx, tonsils,  or paranasal sinuses <Reference refidx="3"/></entry><entry>Asymptomatic or symptomatic</entry></Row><Row><entry>Multiple myeloma</entry><entry>IgG kappa or lambda; or IgA kappa or gamma</entry><entry>Often, multiple lesions of bone</entry><entry>Symptomatic</entry></Row></TBody></TGroup></Table><SummarySection id="_9"><Title>Evaluation of patients with monoclonal (or myeloma) protein (M protein)</Title><Para id="_10">Idiotypic myeloma cells can be found in the blood of myeloma patients in all
stages of the disease.<Reference refidx="4"/><Reference refidx="5"/> For this reason, when treatment is indicated,
systemic treatment must be considered for all patients with symptomatic
plasma cell neoplasms.  Patients with MGUS or asymptomatic, smoldering myeloma do not require
immediate treatment but must be followed carefully for signs of disease
progression.
</Para><Para id="_231">The major challenge is
to separate the stable, asymptomatic group of patients who do not require
treatment from patients with progressive, symptomatic myeloma who should be
treated immediately.<Reference refidx="6"/><Reference refidx="7"/></Para><Para id="_11">Patients with a monoclonal (or myeloma) protein (M protein) in the serum and/or urine are evaluated by some of the following criteria:
</Para><ItemizedList id="_232" Style="bullet" Compact="No"><ListItem>Measure and follow the serum M protein by serum electrophoresis or by specific immunoglobulin (Ig) assays; however, specific Ig quantification always overestimates the M protein because normal
Ig are included in the result.  For this reason,  baseline and
follow-up measurements of the M protein should be done by the same method.<Reference refidx="8"/>
Quantitative serum-free light chains (FLC) may be helpful to follow response if an M protein is not apparent.</ListItem><ListItem>Measure and follow the amount of M-protein light chains excreted in the
urine over 24 hours.  Measure the total amount of protein excreted over 24
hours and multiply this value by the percentage of urine protein that is
M protein, as determined by electrophoresis of concentrated urine protein. An easier, but less accurate, method uses a spot-urine protein electrophoresis.</ListItem><ListItem>Identify the heavy and light chain of the M protein by immunofixation electrophoresis.</ListItem><ListItem>Measure the hemoglobin, leukocyte, platelet, and differential counts.</ListItem><ListItem>Determine the percentage of marrow plasma cells.  Be aware that marrow plasma-cell distribution may vary in different sites. Bone marrow should also be sent for cytogenetics and fluorescence <Emphasis>in situ</Emphasis> hybridization testing for genetics markers of high-risk disease.  (Refer to the  <SummaryRef href="CDR0000062866#_53" url="/types/myeloma/hp/myeloma-treatment-pdq">Genetic Factors and Risk Group</SummaryRef> section of this summary for more information.)</ListItem><ListItem>Measure serum-free kappa and lambda light chain. This is especially useful in cases of oligosecretory plasma-cell dyscrasia or for following cases of light-chain amyloidosis.<Reference refidx="9"/> The FLC ratio  of over 100 can predict a greater than  70% progression within 2 years in patients with smoldering myeloma.<Reference refidx="10"/> </ListItem><ListItem>If clinically warranted, take needle aspirates of a solitary lytic bone lesion, extramedullary
tumor(s), or enlarged lymph node(s) to determine whether these are
plasmacytomas.</ListItem><ListItem>Evaluate renal function with serum creatinine and a creatinine clearance.</ListItem><ListItem>Electrophoresis of concentrated urine protein is very helpful in
differentiating glomerular lesions from tubular lesions.  Glomerular lesions,
such as those resulting from glomerular deposits of amyloid or light-chain
deposition disease, result in the nonselective leakage of all serum proteins
into the urine; the electrophoresis pattern of this urine resembles the serum
pattern with a preponderance of albumin.<Para id="_233">In most myeloma patients, the glomeruli function normally allows only the small molecular weight proteins, such as light chains, to
filter into the urine.  The concentration of protein in the tubules increases
as water is reabsorbed.  This leads to precipitation of proteins and the
formation of tubular casts, which may injure the tubular cells.  With tubular
lesions, the typical electrophoresis pattern shows a small albumin peak and a
larger light-chain peak in the globulin region; this tubular pattern is the
usual pattern found in myeloma patients.</Para></ListItem><ListItem>Measure serum levels of calcium, alkaline phosphatase, lactic
dehydrogenase, and, when indicated by clinical symptoms, cryoglobulins and
serum viscosity.</ListItem><ListItem>Obtain radiographs of the skull, ribs, vertebrae, pelvis, shoulder girdle,
and long bones.
</ListItem><ListItem>Obtain a spinal magnetic resonance imaging (MRI) scan (or spinal computed tomography [CT] or positron emission tomography [PET]-CT scan depending on availability) if the skeletal survey is negative.<Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/></ListItem><ListItem>If amyloidosis is suspected, perform a needle aspiration of subcutaneous
abdominal fat and stain the bone marrow biopsy for amyloid as the easiest and
safest way to confirm the diagnosis.<Reference refidx="14"/></ListItem><ListItem>Measure serum albumin and beta-2-microglobulin as independent
prognostic factors.<Reference refidx="15"/><Reference refidx="16"/></ListItem><ListItem>The presence of circulating myeloma cells is considered a poor prognostic
factor.<Reference refidx="17"/> Primary plasma cell leukemia has a particularly poor prognosis.<Reference refidx="18"/></ListItem></ItemizedList><Para id="_14">These initial studies should be compared with subsequent values at a later
time, when it is necessary to decide whether the disease is stable or
progressive, responding to treatment, or getting worse.</Para><Para id="_15">As mentioned before, the major challenge is
to separate the stable, asymptomatic group of patients who do not require
treatment from patients with progressive, symptomatic myeloma who should be
treated immediately.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="19"/></Para></SummarySection></SummarySection><SummarySection id="_16"><Title>Monoclonal Gammopathy of Undetermined Significance (MGUS)</Title><Para id="_17">Patients with MGUS have an M protein in the serum without findings of multiple
myeloma, macroglobulinemia, amyloidosis, or lymphoma and have fewer than 10%
 of plasma cells in the bone marrow.<Reference refidx="2"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/> Patients with smoldering myeloma have similar characteristics but may have more  than  10% of plasma cells in the bone marrow.  </Para><Para id="_18">These types of patients are asymptomatic and should
not be treated.  Patients with MGUS and risk factors for disease progression, however, must be followed carefully because they are more likely to develop myeloma (most commonly), amyloidosis, lymphoplasmacytic lymphoma, or chronic lymphocytic leukemia   and may
then require therapy.<Reference refidx="22"/><Reference refidx="23"/><Reference refidx="24"/></Para><Para id="_19">Virtually all cases of multiple myeloma are preceded by a gradually rising level of MGUS.<Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/> The annual risk of progression of MGUS to a lymphoid or plasma cell malignancy ranges from 0.5% to 1.0% in population-based cohorts.<Reference refidx="28"/><Reference refidx="29"/> This risk ranges from 2 % to more than 20% in higher-risk patients.</Para><Para id="_20">Risk factors that predict disease progression include the following:</Para><ItemizedList id="_21" Style="bullet"><ListItem>An abnormal serum-FLC ratio.</ListItem><ListItem>Non-IgG class MGUS.</ListItem><ListItem>A high serum-M protein level (≥15 g/L).<Reference refidx="28"/></ListItem></ItemizedList><Para id="_449">	A Swedish cohort study confirmed the higher-risk factors of abnormal serum-FLC ratio and the high serum–monoclonal protein level.<Reference refidx="29"/> They described the additional risk factor of immunoparesis, which is defined as the reciprocal depression of the other Ig classes (if a patient has an IgG kappa M-protein, the IgM and IgA would be below normal levels with “immunoparesis”). Incorporation of gene-expression profiles to better assess risk is also under clinical evaluation.<Reference refidx="30"/> </Para><Para id="_450">	Monoclonal gammopathies that cause organ damage, particularly to the kidney, heart, or peripheral nerves require immediate therapy with the same strategies applied for the conventional plasma-cell dyscrasias.  A monoclonal gammopathy causing renal dysfunction—by direct antibody deposition or amyloidosis—is referred to as monoclonal gammopathy of renal significance. Rising serum creatinine, dropping glomerular filtration rates, and increasing urinary–albumin excretion are all parameters that may signify renal damage and are assessed prospectively for high-risk MGUS patients. Although the N-terminal pro-brain natriuretic peptide is a very sensitive marker for amyloid involvement in the heart, the low specificity must be noted. These extra tests are included with the M-protein level, FLC levels, and FLC  ratio when following patients with MGUS.<Reference refidx="31"/> </Para></SummarySection><SummarySection id="_31"><Title>Isolated Plasmacytoma of Bone</Title><Para id="_32">The patient has an isolated plasmacytoma of the bone if the following are found:</Para><ItemizedList id="_33" Style="bullet"><ListItem>A solitary lytic lesion of plasma cells on skeletal survey in an
otherwise asymptomatic patient.</ListItem><ListItem>A bone marrow examination from an uninvolved
site contains less than  10% plasma cells.<Reference refidx="32"/><Reference refidx="33"/><Reference refidx="34"/></ListItem></ItemizedList><Para id="_34">When clinically indicated, MRI  may reveal
unsuspected bony lesions that were undetected on standard radiographs.  MRI scans of the
total spine may identify other bony lesions.<Reference refidx="35"/></Para></SummarySection><SummarySection id="_35"><Title>Extramedullary Plasmacytoma</Title><Para id="_36">A patient has extramedullary plasmacytoma if the following are found: </Para><ItemizedList id="_37" Style="bullet"><ListItem>Isolated plasma-cell tumors of soft tissues, most commonly
occurring in the tonsils, nasopharynx, or paranasal sinuses.</ListItem><ListItem>Negative findings on skeletal x-rays and bone marrow biopsy.<Reference refidx="36"/><Reference refidx="37"/><Reference refidx="38"/></ListItem></ItemizedList></SummarySection><SummarySection id="_38"><Title>Multiple Myeloma</Title><Para id="_39">Multiple myeloma is a systemic malignancy of plasma cells that typically involves multiple sites within the bone marrow and secretes all or part of a monoclonal antibody. </Para><SummarySection id="_40"><Title>Prognosis</Title><Para id="_42">Multiple myeloma is highly treatable but rarely curable. The median
survival in the prechemotherapy era was about 7 months.  After the introduction
of chemotherapy, prognosis improved significantly with a median survival of 24  to
30 months and a 10-year survival rate of 3%.  Even further improvements in prognosis have occurred because of the introduction of newer therapies such as pulse corticosteroids, thalidomide, lenalidomide, bortezomib, and autologous and allogeneic stem cell transplantation, with median survivals now exceeding 45 to 60 months.<Reference refidx="39"/><Reference refidx="40"/><Reference refidx="41"/><Reference refidx="42"/> Patients with plasma cell leukemia or with soft tissue plasmacytomas (often with plasmablastic morphology) in association with multiple myeloma have poor outcomes.<Reference refidx="18"/><Reference refidx="43"/></Para><Para id="_41">Multiple myeloma is potentially curable when it presents as a
solitary plasmacytoma of bone or as an extramedullary plasmacytoma. (Refer to the <SummaryRef href="CDR0000062866#_31" url="/types/myeloma/hp/myeloma-treatment-pdq">Isolated Plasmacytoma of Bone</SummaryRef> and <SummaryRef href="CDR0000062866#_35" url="/types/myeloma/hp/myeloma-treatment-pdq">Extramedullary Plasmacytoma</SummaryRef> sections of this summary for more information.)</Para></SummarySection></SummarySection><SummarySection id="_43"><Title>Amyloidosis Associated With Plasma Cell Neoplasms </Title><Para id="_44">Multiple myeloma and other plasma cell neoplasms may cause a condition called amyloidosis. Primary amyloidosis can result in severe organ dysfunction especially in the kidney, heart, or peripheral nerves. Clinical symptoms and signs include the following: </Para><ItemizedList id="_371" Style="bullet"><ListItem>Fatigue.</ListItem><ListItem>Purpura.</ListItem><ListItem>Enlarged tongue.</ListItem><ListItem>Diarrhea.</ListItem><ListItem>Edema.</ListItem><ListItem>Lower-extremity paresthesias.</ListItem></ItemizedList><Para id="_372">Elevated serum levels of cardiac troponins, amino-terminal fragment brain-type natriuretic peptide, and serum-FLCs are poor prognostic factors.<Reference refidx="44"/><Reference refidx="45"/> A proposed staging system for primary systemic amyloidosis based on these serum levels requires independent and prospective confirmation.<Reference refidx="44"/>
        </Para></SummarySection><ReferenceSection><Citation idx="1">American Cancer Society: Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society, 2015. <ExternalRef xref="http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf">Available online</ExternalRef>. Last accessed April 1, 2015.</Citation><Citation idx="2" PMID="18021088">Kyle RA, Rajkumar SV: Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 139 (5): 730-43, 2007.</Citation><Citation idx="3" PMID="6668499" MedlineID="84137802">Knowling MA, Harwood AR, Bergsagel DE: Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1 (4): 255-62, 1983.</Citation><Citation idx="4" PMID="7812210" MedlineID="95111363">Zandecki M, Facon T, Preudhomme C, et al.: Significance of circulating plasma cells in multiple myeloma. Leuk Lymphoma 14 (5-6): 491-6, 1994.</Citation><Citation idx="5" PMID="8704185" MedlineID="96290435">Billadeau D, Van Ness B, Kimlinger T, et al.: Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 88 (1): 289-96, 1996.</Citation><Citation idx="6" PMID="12535504" MedlineID="22422929">He Y, Wheatley K, Clark O, et al.: Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev  (1): CD004023, 2003.</Citation><Citation idx="7" PMID="17582068">Kyle RA, Remstein ED, Therneau TM, et al.: Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356 (25): 2582-90, 2007.</Citation><Citation idx="8" PMID="1872571" MedlineID="91336648">Riches PG, Sheldon J, Smith AM, et al.: Overestimation of monoclonal immunoglobulin by immunochemical methods. Ann Clin Biochem 28 ( Pt 3): 253-9, 1991.</Citation><Citation idx="9" PMID="19020545">Dispenzieri A, Kyle R, Merlini G, et al.: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23 (2): 215-24, 2009.</Citation><Citation idx="10" PMID="23183428">Larsen JT, Kumar SK, Dispenzieri A, et al.: Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 27 (4): 941-6, 2013.</Citation><Citation idx="11" PMID="17330855">Horger M, Kanz L, Denecke B, et al.: The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 109 (8): 1617-26, 2007.</Citation><Citation idx="12" PMID="17296972">Walker R, Barlogie B, Haessler J, et al.: Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 25 (9): 1121-8, 2007.</Citation><Citation idx="13" PMID="20410922">Kyle RA, Durie BG, Rajkumar SV, et al.: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24 (6): 1121-7, 2010.</Citation><Citation idx="14" PMID="2451487" MedlineID="88182554">Gertz MA, Li CY, Shirahama T, et al.: Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain). Arch Intern Med 148 (4): 929-33, 1988.</Citation><Citation idx="15" PMID="1509293" MedlineID="92376595">Greipp PR: Advances in the diagnosis and management of myeloma. Semin Hematol 29 (3 Suppl 2): 24-45, 1992.</Citation><Citation idx="16" PMID="2405920" MedlineID="90149148">Durie BG, Stock-Novack D, Salmon SE, et al.: Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood 75 (4): 823-30, 1990.</Citation><Citation idx="17" PMID="8868095" MedlineID="97021735">Greipp PR, Witzig T: Biology and treatment of myeloma. Curr Opin Oncol 8 (1): 20-7, 1996.</Citation><Citation idx="18" PMID="21252060">Pagano L, Valentini CG, De Stefano V, et al.: Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol 22 (7): 1628-35, 2011.</Citation><Citation idx="19" PMID="25439696">Rajkumar SV, Dimopoulos MA, Palumbo A, et al.: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 (12): e538-48, 2014.</Citation><Citation idx="20" PMID="16571879">Kyle RA, Therneau TM, Rajkumar SV, et al.: Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354 (13): 1362-9, 2006.</Citation><Citation idx="21" PMID="12780789">International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121 (5): 749-57, 2003.</Citation><Citation idx="22" PMID="19673884">Bird J, Behrens J, Westin J, et al.: UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 147 (1): 22-42, 2009.</Citation><Citation idx="23" PMID="8649495" MedlineID="96266359">Attal M, Harousseau JL, Stoppa AM, et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 335 (2): 91-7, 1996.</Citation><Citation idx="24" PMID="11856795" MedlineID="21846746">Kyle RA, Therneau TM, Rajkumar SV, et al.: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346 (8): 564-9, 2002.</Citation><Citation idx="25" PMID="19234139">Weiss BM, Abadie J, Verma P, et al.: A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113 (22): 5418-22, 2009.</Citation><Citation idx="26" PMID="19179464">Landgren O, Kyle RA, Pfeiffer RM, et al.: Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113 (22): 5412-7, 2009.</Citation><Citation idx="27" PMID="19478048">Bladé J, Rosiñol L, Cibeira MT: Are all myelomas preceded by MGUS? Blood 113 (22): 5370, 2009.</Citation><Citation idx="28" PMID="15855274">Rajkumar SV, Kyle RA, Therneau TM, et al.: Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106 (3): 812-7, 2005.</Citation><Citation idx="29" PMID="24222331">Turesson I, Kovalchik SA, Pfeiffer RM, et al.: Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood 123 (3): 338-45, 2014.</Citation><Citation idx="30" PMID="24144643">Dhodapkar MV, Sexton R, Waheed S, et al.: Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123 (1): 78-85, 2014.</Citation><Citation idx="31" PMID="24434993">Merlini G: Determining the significance of MGUS. Blood 123 (3): 305-7, 2014.</Citation><Citation idx="32" PMID="16229966">Ozsahin M, Tsang RW, Poortmans P, et al.: Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 64 (1): 210-7, 2006.</Citation><Citation idx="33" PMID="10979944" MedlineID="20435328">Dimopoulos MA, Moulopoulos LA, Maniatis A, et al.: Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96 (6): 2037-44, 2000.</Citation><Citation idx="34" PMID="12057071">Dimopoulos MA, Hamilos G: Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol 3 (3): 255-9, 2002.</Citation><Citation idx="35" PMID="9719116" MedlineID="98383598">Liebross RH, Ha CS, Cox JD, et al.: Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 41 (5): 1063-7, 1998.</Citation><Citation idx="36" PMID="16343803">Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P, et al.: Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 Gy to the target volume improves the local control. Int J Radiat Oncol Biol Phys 64 (4): 1013-7, 2006.</Citation><Citation idx="37" PMID="14512335">Michalaki VJ, Hall J, Henk JM, et al.: Definitive radiotherapy for extramedullary plasmacytomas of the head and neck. Br J Radiol 76 (910): 738-41, 2003.</Citation><Citation idx="38" PMID="10357398" MedlineID="99284290">Alexiou C, Kau RJ, Dietzfelbinger H, et al.: Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 85 (11): 2305-14, 1999.</Citation><Citation idx="39" PMID="17975015">Kumar SK, Rajkumar SV, Dispenzieri A, et al.: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111 (5): 2516-20, 2008.</Citation><Citation idx="40" PMID="18268097">Ludwig H, Durie BG, Bolejack V, et al.: Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 111 (8): 4039-47, 2008.</Citation><Citation idx="41" PMID="17901246">Brenner H, Gondos A, Pulte D: Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111 (5): 2521-6, 2008.</Citation><Citation idx="42" PMID="21410373">Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 364 (11): 1046-60, 2011.</Citation><Citation idx="43" PMID="21900099">Bladé J, Fernández de Larrea C, Rosiñol L, et al.: Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 29 (28): 3805-12, 2011.</Citation><Citation idx="44" PMID="22331953">Kumar S, Dispenzieri A, Lacy MQ, et al.: Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30 (9): 989-95, 2012.</Citation><Citation idx="45" PMID="21220614">Pinney JH, Lachmann HJ, Bansi L, et al.: Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol 29 (6): 674-81, 2011.</Citation></ReferenceSection></SummarySection><SummarySection id="_45"><SectMetaData><SpecificDiagnosis ref="CDR0000037974">multiple myeloma and other plasma cell neoplasms</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information About Plasma Cell Neoplasms</Title><Para id="_46">No generally accepted staging system exists for monoclonal gammopathy of undetermined significance (MGUS), isolated plasmacytoma of bone, or extramedullary plasmacytoma.  Of the plasma cell neoplasms, a staging system exists only for multiple myeloma.</Para><SummarySection id="_234"><Title>Multiple Myeloma</Title><Para id="_47">Multiple myeloma is staged by estimating the myeloma tumor cell mass on the basis of the amount of monoclonal (or myeloma) protein (M protein) in the serum and/or urine, along with various clinical parameters, such as hemoglobin and serum calcium concentrations, the number of lytic bone lesions, and the presence or absence of renal failure. Impaired renal function worsens prognosis regardless of stage.</Para><Para id="_48">The stage of the disease at presentation is a strong determinant of survival, but it has little influence on the choice of therapy since almost all patients, except for rare patients with solitary bone tumors or extramedullary plasmacytomas, have generalized disease.</Para><SummarySection id="_49"><Title>International staging system</Title><Para id="_50">The International Myeloma Working Group studied 11,171 patients, of whom 2,901 received high-dose therapy and 8,270 received only standard-dose therapy.<Reference refidx="1"/></Para><Para id="_51">An International Staging System was derived and is shown below in Table <SummaryRef href="CDR0000062866#_52" url="/types/myeloma/hp/myeloma-treatment-pdq">2</SummaryRef>.<Reference refidx="1"/></Para><Table id="_52"><Title>Table 2.  The International Staging System for Multiple Myeloma</Title><TGroup Cols="3"><ColSpec ColName="col1" ColNum="1" ColWidth="33.33%"/><ColSpec ColName="col2" ColNum="2" ColWidth="33.33%"/><ColSpec ColName="col3" ColNum="3" ColWidth="33.33%"/><THead><Row><entry>Stage</entry><entry>Criteria</entry><entry>Median Survival (mo)</entry></Row></THead><TBody><Row><entry>I</entry><entry>Beta-2-microglobulin &lt;3.5 mg/L and albumin ≥3.5 g/dL</entry><entry>62</entry></Row><Row><entry>II</entry><entry>Beta-2-microglobulin &lt;3.5 mg/L and albumin &lt;3.5 g/dL or beta-2-microglobulin 3.5 mg/L to &lt;5.5 mg/L</entry><entry>44</entry></Row><Row><entry>III</entry><entry>Beta-2-microglobulin ≥5.5 mg/L</entry><entry>29</entry></Row></TBody></TGroup></Table></SummarySection><SummarySection id="_53"><Title>Genetic factors and risk groups
</Title><Para id="_54">Genetic aberrations detected by interphase fluorescence <Emphasis>in situ</Emphasis> hybridization (FISH) may define prognostic groups in retrospective and prospective analyses.<Reference refidx="2"/><Reference refidx="3"/> Short survival and shorter duration of response to therapy have been reported with t(4;14)(p16;q32), t(14; 16)(q32;q23), cytogenetic deletion of 13q-14, and deletion of 17p13 (p53 locus).<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/> The question of whether the choice of therapy based on FISH analysis can influence outcome must await further  study in prospective trials. </Para><Para id="_55">Newer clinical investigations are stratifying patients with multiple myeloma into so-called good-risk, intermediate-risk, and high-risk groups.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/> (See Table <SummaryRef href="CDR0000062866#_442" url="/types/myeloma/hp/myeloma-treatment-pdq">3</SummaryRef> below.) This stratification, based on cytogenetic findings, has been derived from retrospective analyses and requires prospective validation.<Reference refidx="7"/> Bone marrow samples are sent for cytogenetic and FISH analysis. Plasma cell leukemia has a particularly poor prognosis.<Reference refidx="9"/> The otherwise favorable prognosis of hyperploidy is trumped by coexistent adverse cytogenetics.<Reference refidx="10"/></Para><Table id="_442"><Title>Table 3.  Risk Groups for Multiple Myeloma</Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry Align="Center">Risk Group</entry><entry Align="Center">Cytogenetic Findings</entry><entry Align="Center">Disease Characteristics</entry><entry Align="Center">Median Survival</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1">FISH = fluorescence <Emphasis>in situ </Emphasis>hybridization.</entry></Row></TFoot><TBody><Row><entry>Good risk</entry><entry>Has any of the following cytogenetic findings: (1) no adverse FISH or cytogenetics, (2) hyperdiploidy,  (3) t(11;14) by FISH, or (4) t(6;14) by FISH.</entry><entry>These patients most often have  (1) disease that expresses IgG kappa monoclonal gammopathies and (2) lytic bone lesions.</entry><entry>8–10 years</entry></Row><Row><entry>Intermediate risk</entry><entry>t(4;14) by FISH</entry><entry>These patients often have IgA lambda monoclonal gammopathies and less bone disease.</entry><entry>5 years</entry></Row><Row><entry>High risk</entry><entry>Has any of the following cytogenetic findings: (1) del 17p by FISH, (2)  t(14;16) by FISH, (3) cytogenetic del 13, (4) hypodiploidy without adverse cytogenetic findings, (5) 1q gain, or  (6) plasma cell leukemia.</entry><entry>These patients have (1) disease that expresses IgA lambda monoclonal gammopathies (often) and (2) skeletal-related complications (less often).</entry><entry>&lt;2 years</entry></Row></TBody></TGroup></Table></SummarySection></SummarySection><ReferenceSection><Citation idx="1" PMID="15809451">Greipp PR, San Miguel J, Durie BG, et al.: International staging system for multiple myeloma. J Clin Oncol 23 (15): 3412-20, 2005.</Citation><Citation idx="2" PMID="12576322" MedlineID="22640655">Fonseca R, Blood E, Rue M, et al.: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101 (11): 4569-75, 2003.</Citation><Citation idx="3" PMID="17209057">Avet-Loiseau H, Attal M, Moreau P, et al.: Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 109 (8): 3489-95, 2007.</Citation><Citation idx="4" PMID="15976175">Gertz MA, Lacy MQ, Dispenzieri A, et al.: Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106 (8): 2837-40, 2005.</Citation><Citation idx="5" PMID="17024116">Gutiérrez NC, Castellanos MV, Martín ML, et al.: Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21 (1): 143-50, 2007.</Citation><Citation idx="6" PMID="17096015">Sagaster V, Ludwig H, Kaufmann H, et al.: Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 21 (1): 164-8, 2007.</Citation><Citation idx="7" PMID="19955246">Kumar SK, Mikhael JR, Buadi FK, et al.: Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 84 (12): 1095-110, 2009.</Citation><Citation idx="8" PMID="22547600">Avet-Loiseau H, Attal M, Campion L, et al.: Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 30 (16): 1949-52, 2012.</Citation><Citation idx="9" PMID="19877113">Ramsingh G, Mehan P, Luo J, et al.: Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer 115 (24): 5734-9, 2009.</Citation><Citation idx="10" PMID="25428216">Pawlyn C, Melchor L, Murison A, et al.: Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood 125 (5): 831-40, 2015.</Citation></ReferenceSection></SummarySection><SummarySection id="_57"><SectMetaData><SpecificDiagnosis ref="CDR0000037974">multiple myeloma and other plasma cell neoplasms</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment Option Overview for Plasma Cell Neoplasms </Title><Para id="_58">The major challenge in treating plasma cell neoplasms is to separate the stable, asymptomatic group of patients who do not require immediate treatment from patients with progressive, symptomatic myeloma who should be treated immediately.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/> Monoclonal gammopathy of undetermined significance or smoldering myeloma must
be distinguished from progressive myeloma.</Para><SummarySection id="_59"><Title>Asymptomatic Plasma Cell Neoplasms </Title><Para id="_60">Asymptomatic patients with multiple myeloma who have no lytic bone lesions and normal renal function may be initially observed safely outside the context of a clinical trial.<Reference refidx="1"/><Reference refidx="4"/><Reference refidx="5"/> Increasing anemia is the most reliable indicator of progression.<Reference refidx="5"/> The following criteria represent the new definition for smoldering myeloma:<Reference refidx="3"/></Para><ItemizedList id="_455" Style="bullet" Compact="No"><ListItem>Serum monoclonal protein immunoglobulin (Ig) G or IgA of at least  30 g/L or urinary monoclonal protein of at least 500 mg per 24 hours.</ListItem><ListItem>Clonal bone marrow plasma cells 10% to 60% (&gt;60% represents overt myeloma).</ListItem><ListItem>Absence of amyloidosis or myeloma-defining events as follows:<ItemizedList id="_456" Style="dash" Compact="No"><ListItem>Hypercalcemia greater than 1 mg/dl higher than normal.</ListItem><ListItem>Creatinine greater than 2 mg/dl or creatinine clearance less than 40 s/b/min. </ListItem><ListItem>Anemia with hemoglobin less than 10.0 g/dl. </ListItem><ListItem>Bone lesions (one or more) on skeletal radiography, computed tomography (CT)  or positron emission tomography (PET)-CT.</ListItem><ListItem>Clonal plasma cell percentage in marrow of at least 60%.</ListItem><ListItem>Involved: uninvolved serum-free light chain (FLC) ratio of at least 100.</ListItem><ListItem>More than one focal lesion of at least  5 mm on magnetic resonance imaging (MRI) of the spine.</ListItem></ItemizedList></ListItem></ItemizedList></SummarySection><SummarySection id="_61"><Title>Symptomatic Plasma Cell Neoplasms </Title><Para id="_62">Treatment should be given to patients with symptomatic advanced disease .</Para><Para id="_63">Treatment  should be directed at
reducing the tumor cell burden and reversing any complications of disease, such
as renal failure, infection, hyperviscosity, or hypercalcemia, with appropriate
medical management. The International Myeloma Working Group (IMWG) has published new criteria for identifying patients with active myeloma who require therapy.<Reference refidx="3"/> These criteria include the following:
 </Para><ItemizedList id="_457" Style="bullet"><ListItem>Amyloidosis.</ListItem><ListItem>Hypercalcemia greater than 1 mg/dl higher than normal.</ListItem><ListItem>Creatinine greater than 2 mg/dl or creatinine clearance less than 40 s/b/min. </ListItem><ListItem>Anemia with hemoglobin less than 10.0 g/dl. </ListItem><ListItem>Bone lesions (one or more) on skeletal radiography, CT or PET-CT.</ListItem><ListItem>Clonal plasma cell percentage in marrow of at least 60%.</ListItem><ListItem>Involved: uninvolved serum-FLC ratio of at least 100.</ListItem><ListItem>More than one focal lesion of at least  5 mm on MRI of the spine.</ListItem></ItemizedList><Para id="_64">Response criteria have been developed for patients on clinical trials by the IMWG.<Reference refidx="6"/> A very good partial response (VGPR) is defined as a reduction of 90% or more in the serum monoclonal protein and a 24-hour urine monoclonal protein of less than 100 mg. Although not incorporated in the IMWG criteria, many trials report “near complete response (nCR)” when patients have less than 5% bone marrow plasma cells and unmeasurable serum monoclonal proteins but still have positive serum and/or urine immunofixation. Note that these nCR patients are incorporated into the VGPR group by the IMWG. Patients who achieve a CR by IMWG criteria (with a negative immunofixation along with the clear marrow and unmeasurable serum monoclonal proteins) are often said to have attained a “stringent CR” if they also normalize their free kappa/lambda light–chain levels and ratio. The clinical utility of these various categories must be validated in clinical trials. Whether these response definitions will translate into clinically meaningful endpoints, such as overall survival, remains to be seen.</Para><Para id="_65">Current therapy for patients with symptomatic myeloma can be divided into the following categories:</Para><ItemizedList id="_66" Style="bullet"><ListItem>Induction therapies.</ListItem><ListItem>Consolidation therapies, which are less applicable for the very elderly.</ListItem><ListItem>Maintenance therapies.</ListItem><ListItem>Supportive care, such as bisphosphonates. (Refer to the <SummaryRef href="CDR0000062738#_196" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Adjuvant drugs</SummaryRef> section in the <SummaryRef href="CDR0000062738#_69" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pharmacologic Management</SummaryRef> section of the PDQ summary on <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef> for more information.)</ListItem></ItemizedList></SummarySection><ReferenceSection><Citation idx="1" PMID="12535504" MedlineID="22422929">He Y, Wheatley K, Clark O, et al.: Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev  (1): CD004023, 2003.</Citation><Citation idx="2" PMID="17582068">Kyle RA, Remstein ED, Therneau TM, et al.: Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356 (25): 2582-90, 2007.</Citation><Citation idx="3" PMID="25439696">Rajkumar SV, Dimopoulos MA, Palumbo A, et al.: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 (12): e538-48, 2014.</Citation><Citation idx="4" PMID="10755397" MedlineID="20216173">Riccardi A, Mora O, Tinelli C, et al.: Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 82 (7): 1254-60, 2000.</Citation><Citation idx="5" PMID="20026810">Bladé J, Dimopoulos M, Rosiñol L, et al.: Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 28 (4): 690-7, 2010.</Citation><Citation idx="6" PMID="16855634">Durie BG, Harousseau JL, Miguel JS, et al.: International uniform response criteria for multiple myeloma. Leukemia 20 (9): 1467-73, 2006.</Citation></ReferenceSection></SummarySection><SummarySection id="_67"><SectMetaData><SpecificDiagnosis ref="CDR0000041926">primary systemic amyloidosis</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment for Amyloidosis Associated With Plasma Cell Neoplasms </Title><SummarySection id="_68"><Title>Treatment Options for Amyloidosis Associated With Plasma Cell Neoplasms </Title><Para id="_69">Treatment options for amyloidosis associated with plasma cell neoplasms include the following:</Para><OrderedList id="_70" Style="Arabic"><ListItem><SummaryRef href="CDR0000062866#_71" url="/types/myeloma/hp/myeloma-treatment-pdq">Chemotherapy</SummaryRef>, immunomodulatory (IMiDs) agents, and proteasome inhibitors.</ListItem><ListItem><SummaryRef href="CDR0000062866#_74" url="/types/myeloma/hp/myeloma-treatment-pdq">Stem cell rescue</SummaryRef>.</ListItem></OrderedList><SummarySection id="_71"><Title>Chemotherapy</Title><Para id="_73">As is true for all plasma cell dyscrasias, responses have been reported for all the same regimens active in multiple myeloma.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/></Para><Para id="_349">Two randomized trials showed prolonged overall survival (OS) with the use of oral chemotherapy with melphalan with or without colchicine versus colchicine alone.<Reference refidx="10"/><Reference refidx="11"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</Para></SummarySection><SummarySection id="_74"><Title>Stem cell rescue</Title><Para id="_76">A randomized, prospective study of 100 patients with immunoglobulin light-chain amyloidosis compared melphalan plus high-dose dexamethasone with high-dose melphalan plus autologous stem cell rescue.<Reference refidx="12"/> After a median follow-up of 3 years, median OS favored the nontransplant arm (56.9 months  vs. 22.2 months;  <Emphasis>P</Emphasis> = .04).<Reference refidx="12"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]   The 24% transplant-related mortality in this series and others reflects the difficulties involved with high-dose chemotherapy in older patients with organ dysfunction.<Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/> A randomized trial confirming the benefit of autologous transplantation is not anticipated.<Reference refidx="18"/></Para><Para id="_77">An anecdotal series describes full-intensity and reduced-intensity allogeneic stem cell transplantation.<Reference refidx="19"/></Para></SummarySection></SummarySection><SummarySection id="_TrialSearch_67_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_67_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=41926&amp;tt=1&amp;format=2&amp;cn=1">primary systemic amyloidosis</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_67_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="16990593">Wechalekar AD, Goodman HJ, Lachmann HJ, et al.: Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109 (2): 457-64, 2007.</Citation><Citation idx="2" PMID="17008538">Dispenzieri A, Lacy MQ, Zeldenrust SR, et al.: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109 (2): 465-70, 2007.</Citation><Citation idx="3" PMID="16960148">Sanchorawala V, Wright DG, Rosenzweig M, et al.: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 109 (2): 492-6, 2007.</Citation><Citation idx="4" PMID="20085941">Kastritis E, Wechalekar AD, Dimopoulos MA, et al.: Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 28 (6): 1031-7, 2010.</Citation><Citation idx="5" PMID="20724537">Moreau P, Jaccard A, Benboubker L, et al.: Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 116 (23): 4777-82, 2010.</Citation><Citation idx="6" PMID="25202139">Reece DE, Hegenbart U, Sanchorawala V, et al.: Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood 124 (16): 2498-506, 2014.</Citation><Citation idx="7" PMID="22504925">Kumar SK, Hayman SR, Buadi FK, et al.: Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 119 (21): 4860-7, 2012.</Citation><Citation idx="8" PMID="22331187">Venner CP, Lane T, Foard D, et al.: Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119 (19): 4387-90, 2012.</Citation><Citation idx="9" PMID="23479568">Wechalekar AD, Schonland SO, Kastritis E, et al.: A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121 (17): 3420-7, 2013.</Citation><Citation idx="10" PMID="9110907" MedlineID="97244527">Kyle RA, Gertz MA, Greipp PR, et al.: A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336 (17): 1202-7, 1997.</Citation><Citation idx="11" PMID="8629674" MedlineID="96202846">Skinner M, Anderson J, Simms R, et al.: Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100 (3): 290-8, 1996.</Citation><Citation idx="12" PMID="17855669">Jaccard A, Moreau P, Leblond V, et al.: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357 (11): 1083-93, 2007.</Citation><Citation idx="13" PMID="14739213">Dispenzieri A, Kyle RA, Lacy MQ, et al.: Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 103 (10): 3960-3, 2004.</Citation><Citation idx="14" PMID="14734330">Skinner M, Sanchorawala V, Seldin DC, et al.: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140 (2): 85-93, 2004.</Citation><Citation idx="15" PMID="16037390">Leung N, Leung TR, Cha SS, et al.: Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 106 (10): 3353-7, 2005.</Citation><Citation idx="16" PMID="22147893">Madan S, Kumar SK, Dispenzieri A, et al.: High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 119 (5): 1117-22, 2012.</Citation><Citation idx="17" PMID="21828140">Cibeira MT, Sanchorawala V, Seldin DC, et al.: Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 118 (16): 4346-52, 2011.</Citation><Citation idx="18">Mehta  J, Gerta MA, Dispenzieri A: High-dose therapy for amyloidosis: the end of the beginning? Blood  103 (10): 3612-3, 2004.</Citation><Citation idx="19" PMID="16293611">Schönland SO, Lokhorst H, Buzyn A, et al.: Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood 107 (6): 2578-84, 2006.</Citation></ReferenceSection></SummarySection><SummarySection id="_78"><SectMetaData><SpecificDiagnosis ref="CDR0000040134">monoclonal gammopathy of undetermined significance</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment for Monoclonal Gammopathy of Undetermined Significance</Title><SummarySection id="_79"><Title>Treatment Options for Monoclonal Gammopathy of Undetermined Significance (MGUS)</Title><Para id="_80">Treatment options for MGUS include the following:</Para><OrderedList id="_81" Style="Arabic"><ListItem><SummaryRef href="CDR0000062866#_82" url="/types/myeloma/hp/myeloma-treatment-pdq">Watchful waiting</SummaryRef>.</ListItem></OrderedList><SummarySection id="_82"><Title>Watchful waiting</Title><Para id="_83">Multiple myeloma, other plasma cell dyscrasia,
or lymphoma will develop in 12% of patients by 10 years, 25% by 20 years, and 30%
by 25 years. </Para><Para id="_84">All
patients with MGUS should be kept under observation to detect increases in
M protein levels and development of a plasma cell dyscrasia. Higher levels of initial M protein levels may  correlate with increased risk of progression to multiple myeloma.<Reference refidx="1"/><Reference refidx="2"/> In a large retrospective report, the risk of progression at 20 years was 14% for an initial monoclonal protein level of 0.5 g/dL or less, 25% for a level of 1.5 g/dL, 41% for a level of 2.0 g/dL, 49% for a level of 2.5 g/dL, and 64% for a level of 3.0 g/dL.<Reference refidx="1"/></Para><Para id="_85">Treatment
is delayed until the disease progresses to the stage that symptoms or signs
appear.</Para><Para id="_86">Patients with MGUS or smoldering myeloma do not respond more
frequently,  achieve longer remissions, or have improved survival if chemotherapy is
started early while they are still asymptomatic as opposed to waiting for
progression before treatment is initiated.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/> Newer therapies have not been proven to prevent or delay the progression of MGUS to a plasma cell dyscrasia.<Reference refidx="2"/></Para></SummarySection></SummarySection><SummarySection id="_TrialSearch_78_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_78_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=40134&amp;tt=1&amp;format=2&amp;cn=1">monoclonal gammopathy of undetermined significance</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_78_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="11856795" MedlineID="21846746">Kyle RA, Therneau TM, Rajkumar SV, et al.: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346 (8): 564-9, 2002.</Citation><Citation idx="2" PMID="19673884">Bird J, Behrens J, Westin J, et al.: UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 147 (1): 22-42, 2009.</Citation><Citation idx="3" PMID="20026810">Bladé J, Dimopoulos M, Rosiñol L, et al.: Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 28 (4): 690-7, 2010.</Citation><Citation idx="4" PMID="12535504" MedlineID="22422929">He Y, Wheatley K, Clark O, et al.: Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev  (1): CD004023, 2003.</Citation><Citation idx="5" PMID="10755397" MedlineID="20216173">Riccardi A, Mora O, Tinelli C, et al.: Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 82 (7): 1254-60, 2000.</Citation><Citation idx="6" PMID="17582068">Kyle RA, Remstein ED, Therneau TM, et al.: Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356 (25): 2582-90, 2007.</Citation></ReferenceSection></SummarySection><SummarySection id="_87"><SectMetaData><SpecificDiagnosis ref="CDR0000037790">Waldenström macroglobulinemia</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment for Waldenström Macroglobulinemia (Lymphoplasmacytic Lymphoma)</Title><Para id="_88">Refer to the <SummaryRef href="CDR0000062707#_562" url="/types/lymphoma/hp/adult-nhl-treatment-pdq">Lymphoplasmacytic Lymphoma (Waldenström Macroglobulinemia)</SummaryRef> section in  the PDQ summary on <SummaryRef href="CDR0000062707" url="/types/lymphoma/hp/adult-nhl-treatment-pdq">Adult Non-Hodgkin Lymphoma Treatment</SummaryRef> for more information.</Para></SummarySection><SummarySection id="_89"><SectMetaData><SpecificDiagnosis ref="CDR0000041558">isolated plasmacytoma of bone</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment for Isolated Plasmacytoma of Bone</Title><SummarySection id="_90"><Title>Treatment Options for Isolated Plasmacytoma of Bone</Title><Para id="_91">Treatment options for isolated plasmacytoma of bone include the following:</Para><OrderedList id="_92" Style="Arabic"><ListItem><SummaryRef href="CDR0000062866#_93" url="/types/myeloma/hp/myeloma-treatment-pdq">Radiation therapy</SummaryRef> to the lesion.
</ListItem><ListItem><SummaryRef href="CDR0000062866#_96" url="/types/myeloma/hp/myeloma-treatment-pdq">Chemotherapy</SummaryRef> (if the monoclonal [or myeloma] protein [M protein] increases and other evidence of symptomatic multiple
myeloma occurs).</ListItem></OrderedList><SummarySection id="_93"><Title>Radiation therapy</Title><Para id="_94">About 25% of patients have a serum and/or urine M protein; this should disappear following adequate radiation therapy to the lytic lesion. </Para><Para id="_95">The survival rate of patients with
isolated plasmacytoma of bone treated with radiation therapy to the lesion is greater than 50%
at 10 years, which is much better than the survival rate of patients with disseminated multiple
myeloma.<Reference refidx="1"/></Para></SummarySection><SummarySection id="_96"><Title>Chemotherapy</Title><Para id="_97">Most patients will eventually develop disseminated disease and
require chemotherapy; almost 50% of them will do so within 2 years of
diagnosis.<Reference refidx="2"/><Reference refidx="3"/> However, patients with serum paraprotein or Bence Jones
protein, who have complete disappearance of these proteins after radiation
therapy, may be expected to remain free of disease for prolonged periods.<Reference refidx="2"/><Reference refidx="4"/> Patients who progress to multiple myeloma tend to have good responses to
chemotherapy with a median survival of 63 months after progression.<Reference refidx="2"/><Reference refidx="4"/></Para></SummarySection></SummarySection><SummarySection id="_TrialSearch_89_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_89_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=41558&amp;tt=1&amp;format=2&amp;cn=1">isolated plasmacytoma of bone</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_89_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="11316553" MedlineID="21216612">Tsang RW, Gospodarowicz MK, Pintilie M, et al.: Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 50 (1): 113-20, 2001.</Citation><Citation idx="2" PMID="9719116" MedlineID="98383598">Liebross RH, Ha CS, Cox JD, et al.: Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 41 (5): 1063-7, 1998.</Citation><Citation idx="3" PMID="10979944" MedlineID="20435328">Dimopoulos MA, Moulopoulos LA, Maniatis A, et al.: Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96 (6): 2037-44, 2000.</Citation><Citation idx="4" PMID="1548521" MedlineID="92193968">Dimopoulos MA, Goldstein J, Fuller L, et al.: Curability of solitary bone plasmacytoma. J Clin Oncol 10 (4): 587-90, 1992.</Citation></ReferenceSection></SummarySection><SummarySection id="_100"><SectMetaData><SpecificDiagnosis ref="CDR0000041865">extramedullary plasmacytoma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment for Extramedullary Plasmacytoma</Title><SummarySection id="_101"><Title>Treatment Options for Extramedullary Plasmacytoma</Title><Para id="_102">Treatment options for extramedullary plasmacytoma include the following:</Para><OrderedList id="_103" Style="Arabic" Compact="No"><ListItem>Radiation therapy to the isolated lesion with fields that cover
the regional lymph nodes, if possible.<Reference refidx="1"/><Reference refidx="2"/></ListItem><ListItem>In some cases, surgical resection may be considered, but it is usually
followed by radiation therapy.<Reference refidx="2"/>
</ListItem><ListItem>If the monoclonal (or myeloma) protein (M protein) persists or reappears, the patient may need further
radiation therapy.  In some patients, the plasmacytoma may shrink, but not disappear, and
the M protein persists.  These types of patients should be followed closely.  Surgery
should be performed if the plasmacytoma is in a site where it can be removed
easily (e.g., in the tonsil); the M protein may disappear from the blood or
urine.
In other cases, persistence or an increasing M protein may herald progression to multiple myeloma.</ListItem><ListItem>Chemotherapy is required if the disease progresses and causes symptoms.
</ListItem></OrderedList><Para id="_104">Patients with isolated plasma cell tumors of soft tissues, most commonly
occurring in the tonsils, nasopharynx, or paranasal sinuses, should have
skeletal x-rays and bone marrow biopsy (both of which should be negative) and
evaluation for M protein in serum and urine.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/></Para><Para id="_105">About 25% of patients have serum and/or urine M protein; this should disappear following adequate radiation. </Para><Para id="_106">Extramedullary plasmacytoma  is a highly curable disease with progression-free survival ranging from 70% to 87% at 10 to 14 years after treatment with radiation therapy  (with or without previous resection).<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="5"/></Para></SummarySection><SummarySection id="_TrialSearch_100_sid_8"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_100_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=41865&amp;tt=1&amp;format=2&amp;cn=1">extramedullary plasmacytoma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_100_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="11316553" MedlineID="21216612">Tsang RW, Gospodarowicz MK, Pintilie M, et al.: Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 50 (1): 113-20, 2001.</Citation><Citation idx="2" PMID="10357398" MedlineID="99284290">Alexiou C, Kau RJ, Dietzfelbinger H, et al.: Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 85 (11): 2305-14, 1999.</Citation><Citation idx="3" PMID="3102035" MedlineID="87130620">Meis JM, Butler JJ, Osborne BM, et al.: Solitary plasmacytomas of bone and extramedullary plasmacytomas. A clinicopathologic and immunohistochemical study. Cancer 59 (8): 1475-85, 1987.</Citation><Citation idx="4" PMID="1606070" MedlineID="92297509">Soesan M, Paccagnella A, Chiarion-Sileni V, et al.: Extramedullary plasmacytoma: clinical behaviour and response to treatment. Ann Oncol 3 (1): 51-7, 1992.</Citation><Citation idx="5" PMID="12062614" MedlineID="22058041">Strojan P, Soba E, Lamovec J, et al.: Extramedullary plasmacytoma: clinical and histopathologic study. Int J Radiat Oncol Biol Phys 53 (3): 692-701, 2002.</Citation></ReferenceSection></SummarySection><SummarySection id="_107"><SectMetaData><SpecificDiagnosis ref="CDR0000042947">multiple myeloma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment for Multiple Myeloma</Title><SummarySection id="_108"><Title>Initial Evaluation</Title><Para id="_109">The initial approach to the patient is to evaluate the following parameters:</Para><OrderedList id="_110" Style="Arabic"><ListItem>Detection of a monoclonal (or myeloma) protein (M protein) in the serum or urine.
</ListItem><ListItem> Detection of more than 10% of plasma cells on a bone marrow examination.</ListItem><ListItem>Detection of lytic bone lesions or generalized osteoporosis in skeletal
x-rays.</ListItem><ListItem>Presence of soft tissue plasmacytomas.</ListItem><ListItem>Serum albumin and beta-2-microglobulin levels.</ListItem><ListItem>Detection of free kappa and free lambda serum immunoglobulin light chain.<Reference refidx="1"/></ListItem><ListItem>Presence of hypercalcemia.</ListItem><ListItem>Detection of renal dysfunction attributable to the plasma cell dyscrasia (induced by gammopathy or amyloidosis.)</ListItem></OrderedList><Para id="_111">Treatment selection is influenced by
the age and general health of the patient, prior therapy, and the presence of
complications of the disease.<Reference refidx="2"/></Para></SummarySection><SummarySection id="_460"><Title>Therapeutic Overview</Title><Para id="_461">Despite the introduction of many new therapeutic agents over the past two decades, there is still no confirmed curative approach.  Major controversies have resulted regarding the framework for both future trials and current therapeutic recommendations. Unresolved questions in multiple myeloma include the following:</Para><OrderedList id="_462" Style="Arabic" Compact="No"><ListItem>Does a high-dose alkylator-induced immune "reset" after induction therapy (i.e., autologous stem cell transplant [ASCT] consolidation) result in long-term benefits that outweigh potential toxicities such as the emergence of resistant clones or second malignancies? Some clinicians in the United States and many in Europe consider ASCT to be the backbone after induction therapy or after trials introducing new agents into induction therapy.  Other clinicians think that combinations of new agents and the availability of other agents provide the ability to avoid ASCT.</ListItem><ListItem>In choosing initial induction therapy, should new triple-drug regimens (e.g.,  lenalidomide, bortezomib, dexamethasone) be employed to achieve the best response and most durable remission?  Or should active agents be used in singlets and doublets in a sequential fashion, using the same approach as for an indolent lymphoma?  Should this decision be made in a risk-adaptive way, with favorable-prognosis patients employing the sequential approach?  Or should all new patients receive triple-drug regimens?</ListItem><ListItem>As newer agents, such as carfilzomib and pomalidomide, and newer innovations (e.g.,  the anti-CD38 monoclonal antibodies under investigation) are used, will the stringent complete remissions equal or surpass ASCT with less long-term toxicities?</ListItem><ListItem>Maintenance therapies are under active clinical evaluation; the prolonged remissions and improved progression-free survival (PFS) have not translated into established overall survival (OS) benefits in most trials. (Refer to the <SummaryRef href="CDR0000062866#_201" url="/types/myeloma/hp/myeloma-treatment-pdq">Maintenance Therapy</SummaryRef> section of this summary for more information.) How will this approach augment induction and consolidation therapies?<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/></ListItem></OrderedList><Para id="_463">Several questions are raised when therapy is chosen for a patient with symptomatic myeloma at first presentation:</Para><OrderedList id="_464" Style="Arabic" Compact="No"><ListItem>Is the patient eligible for a clinical trial? The sequence and combinations of new and older therapies can be determined only by prospective clinical trials.</ListItem><ListItem>Does the patient have comorbidities? Age, organ dysfunction, and risk of cardiovascular and thrombotic complications  influence the choice of induction therapies and consideration of consolidation therapies, such as ASCT.</ListItem></OrderedList><Para id="_465">In summary, clinicians utilize a clinical trial or one of the following strategies for a newly diagnosed patient with multiple myeloma:</Para><OrderedList id="_466" Style="Arabic" Compact="No"><ListItem>A risk-adapted approach using single agents or doublets sequentially and re-using previous successful regimens before proceeding to newer agents (the indolent lymphoma/leukemia approach).  Maintenance therapy can be implemented along the way.</ListItem><ListItem>Induction using a triple-drug approach to maximize durable response first and then to implement new agents on protocols (avoiding ASCT). Maintenance therapy can be implemented along the way.</ListItem><ListItem>Induction using a doublet or triplet or using new drugs in an investigative setting en route to ASCT consolidation followed by maintenance therapy.</ListItem></OrderedList><Para id="_467">There are regional geographic variations to the approaches listed.  Clinical trials and future discoveries should help to explicate the best therapeutic strategy.</Para></SummarySection><SummarySection id="_112"><Title>Induction Therapy</Title><SummarySection id="_116"><Title>Induction therapy agents</Title><Para id="_117">Multiple therapeutic agents are available for induction therapy, either alone or in combinations.<Reference refidx="9"/> These include the following:</Para><ItemizedList id="_118" Style="bullet"><ListItem>Steroids (e.g., dexamethasone and prednisone).</ListItem><ListItem>Immunomodulatory drugs (IMiDs).<ItemizedList id="_350" Style="bullet"><ListItem>Lenalidomide.</ListItem><ListItem>Pomalidomide.</ListItem><ListItem>Thalidomide.</ListItem></ItemizedList></ListItem><ListItem>Proteasome inhibitors.<ItemizedList id="_351" Style="bullet"><ListItem>Bortezomib.</ListItem><ListItem>Carfilzomib.</ListItem></ItemizedList></ListItem><ListItem>Alkylating agents (e.g., melphalan and cyclophosphamide).</ListItem><ListItem>Other cytotoxic drugs (e.g., vincristine, doxorubicin, and liposomal doxorubicin).</ListItem><ListItem>Histone deacetylase inhibitors.</ListItem><ListItem>Ponatinib (in combination with bortezomib).</ListItem></ItemizedList><Para id="_119">Clinical trials are needed to establish  the regimens with the best efficacy and least long-term toxicity.  (Refer to the <SummaryRef href="CDR0000062866#_165" url="/types/myeloma/hp/myeloma-treatment-pdq">Combination therapy</SummaryRef> section of this summary for a list of current clinical trials.)</Para></SummarySection><SummarySection id="_120"><Title>Guidelines for choosing induction therapy</Title><Para id="_121">Until results become available, outside the context of a clinical trial, clinicians may choose induction therapy based on the following guidelines:</Para><OrderedList id="_122" Style="Arabic" Compact="No"><ListItem>In patients younger than  70 years, alkylators are avoided up front to avoid stem cell toxicity with subsequent risks for cytopenias, secondary malignancies, or poor stem cell harvesting if transplantation is considered for consolidation therapy.<Reference refidx="10"/></ListItem><ListItem>Bortezomib and/or lenalidomide is combined with dexamethasone for at least 8 months or until best response if consolidation therapy is planned.<Reference refidx="11"/><Reference refidx="12"/>  (Refer to the <SummaryRef href="CDR0000062866#_381" url="/types/myeloma/hp/myeloma-treatment-pdq">Lenalidomide</SummaryRef> and <SummaryRef href="CDR0000062866#_392" url="/types/myeloma/hp/myeloma-treatment-pdq">Bortezomib</SummaryRef> sections of this summary for more information; also refer to the <SummaryRef href="CDR0000062866#_460" url="/types/myeloma/hp/myeloma-treatment-pdq">Therapeutic Overview</SummaryRef> section of this summary  for a discussion about the controversy of using doublets or triplets.)</ListItem><ListItem>The choice of bortezomib or lenalidomide is based on side-effect profile and route of administration.  <ItemizedList id="_228" Style="bullet" Compact="No"><ListItem>Bortezomib is given subcutaneously and can cause neuropathic toxicities.<Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/> Bortezomib is preferred in the setting of renal impairment.<Reference refidx="15"/></ListItem><ListItem>Lenalidomide is given orally and can cause an increased risk for deep venous thrombosis (DVT), requiring additional prophylactic medication.<Reference refidx="11"/><Reference refidx="16"/></ListItem></ItemizedList></ListItem><ListItem>Patients with standard-risk disease, as defined in the <SummaryRef href="CDR0000062866#_45" url="/types/myeloma/hp/myeloma-treatment-pdq">Stage Information About  Plasma Cell Neoplasms</SummaryRef> section of this summary, might receive induction therapy alone, followed by careful observation after best response.<Reference refidx="17"/> (Refer to the <SummaryRef href="CDR0000062866#_460" url="/types/myeloma/hp/myeloma-treatment-pdq">Therapeutic Overview</SummaryRef> section of this summary for a discussion about the controversy of using a risk-adapted approach in some cases.)</ListItem><ListItem>  Patients with high-risk disease might receive triple-drug induction therapy until best response, followed by consolidation therapy with allogeneic or ASCT.<Reference refidx="17"/></ListItem></OrderedList><Para id="_124">These guidelines require validation by ongoing clinical trials; participation in clinical trials is the preferred choice, when possible.</Para></SummarySection><SummarySection id="_125"><Title>Corticosteroids</Title><Para id="_126">Since the mid-1980s, dexamethasone has been administered at a dose of 40 mg orally for 4 consecutive days, which is  the same schedule used with the vincristine plus doxorubicin plus dexamethasone (VAD) regimen.<Reference refidx="18"/>  Response rates of 60% to 70% in previously untreated patients appeared to be as high as those in patients treated with VAD.<Reference refidx="18"/><Reference refidx="19"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</Para><Para id="_127">Evidence (corticosteroids):</Para><Para id="_128">A prospective trial randomly assigned 488 patients older than  65 years to receive dexamethasone alone, melphalan plus dexamethasone, dexamethasone plus interferon-alpha, and melphalan plus prednisone (MP).</Para><ItemizedList id="_129" Style="bullet" Compact="No"><ListItem>With a median follow-up of 7.1 years, no difference was observed in OS (median survival times were 32 months–40 months).<Reference refidx="20"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</ListItem><ListItem>The patients on the dexamethasone-based arms had significantly more infections, glucose intolerance, gastrointestinal symptoms, and psychiatric complaints. (Refer to the PDQ summary on <SummaryRef href="CDR0000062736" url="/about-cancer/treatment/side-effects/constipation/GI-complications-hp-pdq">Gastrointestinal Complications</SummaryRef> for more information on gastrointestinal symptoms.)</ListItem></ItemizedList><Para id="_130"> There has never been a randomized trial comparing single-agent oral dexamethasone at a traditional high dose (40 mg a day for 4 days, repeated after 4 days off) with a lower dose (≤40 mg weekly). This issue of dexamethasone dose has been evaluated in two of the following prospective, randomized trials:</Para><ItemizedList id="_131" Style="bullet" Compact="No"><ListItem>In the context of melphalan, as evaluated in a National Cancer Institute of Canada trial (<ProtocolRef href="CDR0000651985" nct_id="NCT00002678">CAN-NCIC-MY7</ProtocolRef>).<ItemizedList id="_132" Style="dash"><ListItem>Compared with standard-dose steroids,  high-dose dexamethasone was associated with an increased risk of infection in the melphalan trial, but there was no difference in efficacy.<Reference refidx="21"/></ListItem></ItemizedList></ListItem><ListItem>In the context of lenalidomide, as evaluated in an Eastern Cooperative Oncology Group trial (<ProtocolRef href="CDR0000653732" nct_id="NCT00098475">ECOG-E4A03</ProtocolRef>).<Reference refidx="11"/><ItemizedList id="_133" Style="dash"><ListItem>The lenalidomide study questioned the safety and efficacy of high-dose dexamethasone.<Reference refidx="11"/> (Refer to the <SummaryRef href="CDR0000062866#_381" url="/types/myeloma/hp/myeloma-treatment-pdq">Lenalidomide</SummaryRef> section of this summary for more information.)</ListItem></ItemizedList></ListItem></ItemizedList><Para id="_134">On the basis of these trials, almost all ongoing clinical trials in the United States and Europe  have implemented the low-dose dexamethasone schedule with or without other therapeutic agents: 40 mg dexamethasone (oral [PO] or intravenous [IV]) weekly in younger patients or fit older patients or 20 mg dexamethasone (PO or IV) in less-fit older patients.</Para></SummarySection><SummarySection id="_352"><Title>IMiDs (immunomodulatory drugs)</Title><SummarySection id="_381"><Title>Lenalidomide</Title><Para id="_382">Evidence (lenalidomide):</Para><OrderedList id="_383" Style="Arabic" Compact="No"><ListItem>A prospective, randomized study of 351 relapsed patients compared lenalidomide, an analog of thalidomide, plus high-dose dexamethasone with high-dose dexamethasone plus placebo.<Reference refidx="22"/><ItemizedList id="_384" Style="bullet" Compact="No"><ListItem>The lenalidomide combination showed a significantly higher time to tumor progression (11.3 months vs. 4.7 months, <Emphasis>P</Emphasis> &lt; .001) with a 16-month median follow-up, and median OS had not been reached, versus 20.6 months in the placebo group (hazard ratio [HR] = 0.66, 95% confidence interval [CI], 0.45–0.96, <Emphasis>P</Emphasis> = .03).<Reference refidx="22"/>[<LOERef href="CDR0000335106">Level of evidence: 1iA</LOERef>]</ListItem><ListItem>The lenalidomide-containing arm had more DVT (11.4% vs. 4.6%).<Reference refidx="22"/></ListItem></ItemizedList></ListItem><ListItem>Similarly, another randomized, prospective trial (<ProtocolRef href="CDR0000600246" nct_id="NCT00056160">NCT00056160</ProtocolRef>) of 353 previously treated patients favored the lenalidomide plus high-dose dexamethasone arm  versus dexamethasone plus placebo.<ItemizedList id="_385" Style="bullet" Compact="No"><ListItem>With a median follow-up of 26 months, the median time to progression was 11.1 months versus 4.7 months (<Emphasis>P</Emphasis> &lt; .001), and the median OS was 29.6 months versus 20.2 months (<Emphasis>P</Emphasis> &lt;  .001).<Reference refidx="23"/>[<LOERef href="CDR0000335106">Level of evidence: 1iA</LOERef>] </ListItem></ItemizedList></ListItem><ListItem>A prospective, randomized study (<ProtocolRef href="CDR0000653732" nct_id="NCT00098475">ECOG-E4A03</ProtocolRef>) of 445 untreated symptomatic patients compared lenalidomide and high-dose dexamethasone (40 mg on days 1–4, 9–12, and 17–20, every 28 days) with lenalidomide and low-dose dexamethasone (40 mg on days 1, 8, 15, and 22, every 28 days).<Reference refidx="11"/><ItemizedList id="_386" Style="bullet" Compact="No"><ListItem>With a median follow-up of 36 months, this trial showed improved OS for patients in the low-dose dexamethasone arm (87% vs. 75% at 2 years, <Emphasis>P</Emphasis> = .006), despite no difference in progression-free survival (PFS).<Reference refidx="11"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</ListItem><ListItem>The extra deaths on the high-dose dexamethasone arm were attributed to cardiopulmonary toxicity and faster progression with subsequent therapies.  DVTs were also more frequent in the high-dose arm (25% vs. 9%).</ListItem><ListItem>OS favored the low-dose arm with a 2-year survival of 87% versus 75% in the high-dose arm (<Emphasis>P</Emphasis> = .006).<Reference refidx="11"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] The low-dose dexamethasone arm with lenalidomide had less than 5% DVT with aspirin alone.</ListItem></ItemizedList></ListItem><ListItem>A prospective, randomized study of 1,623 transplant-ineligible, untreated patients compared lenalidomide and low-dose dexamethasone when given until progression with a 72-week induction regimen versus melphalan plus prednisone plus thalidomide (MPT) for 72 weeks.<Reference refidx="24"/><ItemizedList id="_458" Style="bullet" Compact="No"><ListItem>With a median follow-up of 37 months, this trial showed improved OS for patients on the continuous lenalidomide plus dexamethasone (59% vs. 51% for MPT at 4 years, HR, 0.78; 95% CI, 0.64–0.96, <Emphasis>P</Emphasis> = .02).[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</ListItem><ListItem>Although median PFS was 5 months longer for continuous lenalidomide plus dexamethasone versus 72 weeks of the same regimen (HR, 0.70; 95% CI, 0.60–0.82;  <Emphasis>P</Emphasis> &lt; .001), there was no difference in OS.[<LOERef href="CDR0000335131">Level of evidence: 1iiDiii</LOERef>]</ListItem></ItemizedList></ListItem><ListItem>A retrospective analysis of 353 patients who received lenalidomide and high-dose dexamethasone found that the 17% of the patients who experienced a thromboembolic episode had no decrease in OS or time to progression.<Reference refidx="25"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>]</ListItem></OrderedList><Para id="_387">Lenalidomide has substantially greater myelosuppression but less neuropathy than seen with thalidomide; however, both have the same tendency for DVT.<Reference refidx="11"/><Reference refidx="22"/><Reference refidx="23"/><Reference refidx="25"/> A randomized, prospective trial of 342 previously untreated patients receiving lenalidomide-containing regimens compared aspirin (100 mg/day) with enoxaparin (40 mg/day); the 2% incidence of venous thromboembolic events was similar for both interventions.<Reference refidx="26"/> Empirically, the greater the number of risk factors for DVT, the more intense the recommendation for prophylactic anticoagulation.  (Refer to the  <SummaryRef href="CDR0000062866#_468" url="/types/myeloma/hp/myeloma-treatment-pdq">Thalidomide</SummaryRef> section of this summary for more information about risk factors.) </Para><Para id="_388">A retrospective review of almost 4,000 relapsed or refractory patients who received lenalidomide in 11 clinical trials suggested an increased incidence of nonmelanoma skin cancers.<Reference refidx="27"/> As a result of  predominant renal clearance, lenalidomide doses need to be reduced in the setting of impaired renal function (creatinine clearance, 30–50: 10 mg per day; creatinine clearance, &lt;30: 15 mg every other day; dialysis, 15 mg on day after dialysis).<Reference refidx="28"/> Uncontrolled trials, including <ProtocolRef href="CDR0000447326" nct_id="NCT00151203">NCT00151203</ProtocolRef>, have added clarithromycin (500 mg twice a day) to lenalidomide and dexamethasone with a claim of increased response rates; controlled studies are required to establish the value of this approach.<Reference refidx="29"/></Para></SummarySection><SummarySection id="_389"><Title>Pomalidomide</Title><Para id="_390">Evidence (pomalidomide):</Para></SummarySection><OrderedList id="_391" Style="Arabic" Compact="No"><ListItem>Several phase I and II trials in heavily pretreated patients after bortezomib and lenalidomide showed a response rate ranging from 26% to 63%.<Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>] Although pomalidomide is taken orally like thalidomide and lenalidomide, pomalidomide causes less neuropathy and asthenia than thalidomide and less myelosuppression and skin rashes than lenalidomide.</ListItem><ListItem>For 302 patients with relapsed or refractory disease, a pomalidomide and low-dose dexamethasone regimen was compared with high-dose dexamethasone in a randomized prospective trial; after a median follow-up of 10.0 months, the PFS favored the pomalidomide arm by 4.0 to 1.9 months (HR, 0.48; 95% CI, 0.39–0.60; <Emphasis>P</Emphasis> &lt; .0001).<Reference refidx="33"/>[<LOERef href="CDR0000335131">Level of evidence: 1iiDiii</LOERef>]</ListItem></OrderedList><Para id="_451">	Pomalidomide was approved for patients who relapse after two previous regimens, which must have included bortezomib and lenalidomide. Although some myelosuppression and increased risk of thromboembolic events are noted as with lenalidomide and thalidomide, very little peripheral neuropathy is noted in comparison with  the other agents.<Reference refidx="34"/></Para><SummarySection id="_468"><Title>Thalidomide</Title><Para id="_469">Evidence (thalidomide):</Para><Para id="_470">Eleven randomized prospective studies involving more than 4,600  patients have examined the introduction of thalidomide as induction therapy for previously untreated symptomatic patients with multiple myeloma.<Reference refidx="35"/><Reference refidx="36"/><Reference refidx="37"/><Reference refidx="38"/><Reference refidx="39"/><Reference refidx="40"/><Reference refidx="41"/><Reference refidx="42"/><Reference refidx="43"/><Reference refidx="44"/></Para><ItemizedList id="_471" Style="bullet" Compact="No"><ListItem>All of the trials reported improved response rates with the introduction of thalidomide and no hematopoietic damage, allowing adequate stem cell collection when applicable or allowing combinations with other myelosuppressive agents.</ListItem><ListItem>Only two of the eleven randomized studies reported a survival advantage using thalidomide. In these trials, the patients older than 65 or 75 years at the  2-year follow-ups showed a 44- to 56-month median OS for MP plus thalidomide versus 28- to 30-month median OS  for MP (<Emphasis>P</Emphasis> &lt; .03 in both studies).<Reference refidx="41"/><Reference refidx="45"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] </ListItem><ListItem>A possible explanation is that the two trials used a lower dose of thalidomide than the other studies (100 mg vs. ≥200 mg), a lower dose of steroids (60 mg of prednisone vs. high-dose dexamethasone), and involved the use of alkylating agents.</ListItem></ItemizedList><Para id="_472">As previously described in the section on <SummaryRef href="CDR0000062866#_125" url="/types/myeloma/hp/myeloma-treatment-pdq">corticosteroids</SummaryRef>, high-dose dexamethasone can complicate interpretation of clinical trials by worsening cardiopulmonary toxicity and deaths, especially in the context of thalidomide or lenalidomide, both of which are thrombogenic agents.  </Para><Para id="_473">Factors that have been implicated to worsen the risk of DVT include  the use of high-dose dexamethasone, concomitant erythropoietic growth factors, and concomitant doxorubicin, liposomal doxorubicin, or alkylating agents.<Reference refidx="46"/><Reference refidx="47"/></Para><Para id="_474">Personal cardiovascular risk factors can also influence the rate of DVT.  Various clinical trials have included different DVT prophylaxis measures, including aspirin (81 mg–100 mg a day), warfarin, or low molecular-weight heparin.<Reference refidx="39"/><Reference refidx="47"/><Reference refidx="48"/> In a randomized, prospective trial, 667 previously untreated patients who received thalidomide-containing regimens were randomly assigned to aspirin (100 mg/day), warfarin (1.25 mg/day) or enoxaparin (40 mg/day).  The rate of serious thromboembolic events, acute cardiovascular events, or sudden death was 6.5% and similar for all three interventions.<Reference refidx="49"/></Para><Para id="_475">Prospective electrophysiologic monitoring provides no clear benefit over clinical evaluation for the development of clinically significant neuropathy while on thalidomide.<Reference refidx="50"/></Para><Para id="_476">Late in the disease course, when all other options have failed, thalidomide can be employed, sometimes with durable responses.<Reference refidx="46"/>  By utilizing a low dose (50 mg PO daily), significant sedation, constipation, and neuropathy may be avoided. Prophylaxis to avoid thrombosis with aspirin, warfarin, or low molecular–weight heparin is required; the choice of therapy depends on pre-existing risk factors.</Para></SummarySection></SummarySection><SummarySection id="_356"><Title>Proteasome inhibitors</Title><SummarySection id="_392"><Title>Bortezomib</Title><Para id="_393">Evidence (bortezomib):</Para><OrderedList id="_394" Style="Arabic" Compact="No"><ListItem>A prospective, randomized trial (the <ProtocolRef href="CDR0000522898" nct_id="NCT00111319">VISTA</ProtocolRef> trial [NCT00111319])  of 682 previously untreated symptomatic patients who were not candidates for stem cell transplantation (SCT) because of  age (one-third of patients &gt;75 years) compared bortezomib combined with melphalan and prednisone with melphalan and prednisone alone.<Reference refidx="12"/><ItemizedList id="_395" Style="bullet" Compact="No"><ListItem>With a median follow-up of 60 months, the median OS favored the bortezomib arm (56.4 vs. 43.1 months, <Emphasis>P</Emphasis> &lt; .001).<Reference refidx="51"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</ListItem></ItemizedList></ListItem><ListItem>A prospective, randomized study of 669 patients with relapsing myeloma, who had been treated previously with steroids,  compared intravenous bortezomib with high-dose oral dexamethasone.<ItemizedList id="_396" Style="bullet" Compact="No"><ListItem>With a median follow-up of 22 months, the median OS was 29.8 months for bortezomib versus 23.7 months for dexamethasone (HR,  0.77; <Emphasis>P</Emphasis> = .027), despite 62% of dexamethasone patients crossing over to receive bortezomib.<Reference refidx="13"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</ListItem><ListItem>Bortezomib-associated peripheral neuropathy is reversible in most patients after dose reduction or discontinuation.<Reference refidx="14"/><Reference refidx="52"/><Reference refidx="53"/></ListItem></ItemizedList></ListItem><ListItem>A prospective, randomized trial (<ProtocolRef href="CDR0000420968" nct_id="NCT00103506">NCT00103506</ProtocolRef>) of 646 previously treated patients compared bortezomib plus pegylated liposomal doxorubicin with bortezomib alone.<Reference refidx="54"/><ItemizedList id="_397" Style="bullet" Compact="No"><ListItem>With a median follow-up of 7 months, the combination was better in both median time to progression (9.3 months vs. 6.5 months, <Emphasis>P</Emphasis> &lt; .001) and in OS (82% vs. 75%, <Emphasis>P</Emphasis> = .05).<Reference refidx="54"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</ListItem></ItemizedList></ListItem><ListItem>Two studies compared bortezomib plus thalidomide plus dexamethasone versus thalidomide plus dexamethasone after SCT  and showed improved PFS (3-year PFS of 68% vs. 48% [<Emphasis>P </Emphasis> = .042] in previously untreated patients and median PFS of 20 months versus 14 months in relapsed patients [<Emphasis>P</Emphasis> = .001]) but no difference in OS.<Reference refidx="55"/><Reference refidx="56"/>[<LOERef href="CDR0000335131">Level of evidence: 1iiDiii</LOERef>]</ListItem><ListItem>In 511 previously untreated patients not eligible for transplant and older than 65 years, a randomized comparison of bortezomib plus melphalan plus prednisone plus thalidomide plus subsequent maintenance used bortezomib plus thalidomide versus bortezomib plus melphalan plus prednisone (with no maintenance) and showed superiority of the arm with thalidomide and bortezomib during induction and maintenance.  <ItemizedList id="_398" Style="bullet" Compact="No"><ListItem>With a median follow-up of 54 months, 3-year PFS was 35% versus 25% (<Emphasis>P</Emphasis> &lt; . 001), and 5-year OS was 61% versus 51% (<Emphasis>P</Emphasis> = .01).<Reference refidx="57"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] Because of trial design, it is unclear  whether the improved results were caused by  the addition of thalidomide during induction or by  the use of maintenance therapy with bortezomib and thalidomide.</ListItem></ItemizedList></ListItem><ListItem>In 827 previously untreated patients, a randomized comparison of bortezomib plus doxorubicin plus dexamethasone followed by high-dose melphalan plus autologous SCT plus bortezomib maintenance for 2 years versus vincristine plus doxorubicin plus dexamethasone followed by the same SCT consolidation plus thalidomide maintenance showed superiority of the arm with bortezomib during induction and maintenance.<Reference refidx="58"/>[<LOERef href="CDR0000335131">Level of evidence: 1iiDiii</LOERef>]<ItemizedList id="_399" Style="bullet" Compact="No"><ListItem>With a median follow-up of 41 months, the median PFS was 35 months versus 28 months in favor of the bortezomib arm (<Emphasis>P</Emphasis> = .002) with no significant difference in OS.<Reference refidx="58"/></ListItem></ItemizedList></ListItem></OrderedList><Para id="_400">Because bortezomib is metabolized and cleared by the liver, it appears active and well tolerated in patients with renal impairment.<Reference refidx="15"/><Reference refidx="59"/> In several retrospective, nonrandomized comparisons, bortezomib administered once weekly had significantly less grade 3 to 4 peripheral neuropathy (2%–8% vs. 13%–28%) with no loss of efficacy compared with standard biweekly administration.<Reference refidx="60"/><Reference refidx="61"/></Para><Para id="_401">In a randomized, prospective trial, subcutaneous injections of bortezomib were compared with intravenous infusions in the usual schedule (days 1, 4, 8, 11).<Reference refidx="62"/> After a median follow-up of 1 year, grade 3 to 4 neurologic toxicity was reduced from 16% to 6% (<Emphasis>P</Emphasis> = .026) using the subcutaneous route, with no perceived loss of efficacy in terms of response.  However, this study was not powered for noninferiority of response.  New clinical trials are employing  these changes of weekly treatment and subcutaneous route to improve the safety profile of bortezomib-containing regimens. In this trial, the bisphosphonates were continued until the time of relapse.</Para><Para id="_452">More than 6 months after completion of bortezomib induction therapy, bortezomib can be applied again with a 40% overall response rate, according to one anecdotal phase II trial.<Reference refidx="63"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</Para></SummarySection><SummarySection id="_402"><Title>Carfilzomib</Title><Para id="_403">Evidence (carfilzomib):</Para><OrderedList id="_404" Style="Arabic" Compact="No"><ListItem>A prospective, randomized study of 792 relapsed patients compared carfilzomib plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone.<Reference refidx="64"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]<ItemizedList id="_459" Style="bullet" Compact="No"><ListItem>With a median follow-up of 32 months, the median PFS was improved with the addition of carfilzomib: 26.3 months versus 17.6 months (HR, 0.69; 95% CI, 0.57–0.83, <Emphasis>P </Emphasis> = .0001).</ListItem><ListItem>The 24-month OS favored the addition of carfilzomib 73% versus 65% (HR, 0.79; 95% CI,  0.63–0.99, <Emphasis>P</Emphasis> = .04).</ListItem></ItemizedList></ListItem><ListItem>In newly diagnosed patients aged 65 and older, carfilzomib combined with cyclophosphamide and dexamethasone in a phase II trial with 58 patients achieved at least a partial response in 95% of the patients and a near complete response (nCR) or stringent complete response (sCR) in 48% of the patients.<Reference refidx="65"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</ListItem><ListItem>In 53 patients with newly diagnosed disease, carfilzomib combined with lenalidomide and dexamethasone achieved an nCR or sCR in 62% of the patients and  a 24-month PFS of 92%.<Reference refidx="66"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]. </ListItem><ListItem>In 52 patients with relapsed disease, this combination achieved an overall response rate of 77% and a 15-month PFS with a median follow-up of 24 months.<Reference refidx="67"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</ListItem></OrderedList></SummarySection></SummarySection><SummarySection id="_158"><Title>Conventional-dose chemotherapy</Title><Para id="_159">Evidence (conventional-dose chemotherapy):</Para><Para id="_160">The VAD regimen has shown activity in previously treated and in untreated patients with response rates ranging from 60% to 80%.<Reference refidx="68"/><Reference refidx="69"/><Reference refidx="70"/><Reference refidx="71"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</Para><ItemizedList id="_161" Style="bullet" Compact="No"><ListItem>No randomized studies support the widespread use of this regimen in untreated patients. </ListItem><ListItem>This regimen avoids early exposure to alkylating agents, thereby minimizing any problems with stem cell collection (if needed) and any future risks for myelodysplasia or secondary leukemia.</ListItem><ListItem>Disadvantages include the logistics for a 96-hour infusion of doxorubicin and a  low CR rate.  </ListItem><ListItem>An alternative version of VAD substitutes pegylated liposomal doxorubicin for doxorubicin, eliminates the need for an infusion, and provides comparable response rates.<Reference refidx="72"/><Reference refidx="73"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</ListItem></ItemizedList><Para id="_162">Evidence is not strong that any alkylating agent is superior to any other. 
All standard doses and schedules produce equivalent results.<Reference refidx="74"/> The two  most common regimens historically have been oral MP and oral cyclophosphamide plus prednisone.<Reference refidx="74"/><Reference refidx="75"/><Reference refidx="76"/></Para><Para id="_163">Combinations, such as those used in EST-2479, of alkylating agents and prednisone, administered  simultaneously or
alternately, have not proven to be superior to therapy with
MP.<Reference refidx="77"/><Reference refidx="78"/><Reference refidx="79"/><Reference refidx="80"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</Para><Para id="_164">A meta-analysis of studies
comparing MP with drug combinations concluded that both
forms of treatment were equally effective.<Reference refidx="74"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] Patients who relapsed after initial therapy with cyclophosphamide and
prednisone had no difference in OS (median OS, 17 months) when
randomly assigned  to  receive vincristine plus carmustine plus melphalan plus
cyclophosphamide plus prednisone or VAD.<Reference refidx="81"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] 
</Para></SummarySection><SummarySection id="_165"><Title>Combination therapy</Title><Para id="_166">Evidence (combination therapy):</Para><Para id="_167">Several national and international trials have been implemented to define the optimal combination regimens.  Participation in these trials should be the preferred approach, when feasible.  The combination regimens in these trials represent the most successful from numerous phase II reports during the last several years.</Para><ItemizedList id="_168" Style="bullet" Compact="No"><ListItem><ProtocolRef href="CDR0000561758" nct_id="NCT00522392">ECOG-E1A05</ProtocolRef>: Bortezomib + dexamethasone versus lenalidomide + bortezomib + dexamethasone.<Reference refidx="82"/> </ListItem><ListItem><ProtocolRef href="CDR0000590321" nct_id="NCT00644228">SWOG-S0777</ProtocolRef>: Lenalidomide + dexamethasone versus  lenalidomide + bortezomib + dexamethasone.</ListItem><ListItem><ProtocolRef href="CDR0000561818" nct_id="NCT00507442">EVOLUTION</ProtocolRef> (NCT00507442) trial: Bortezomib + lenalidomide + dexamethasone versus bortezomib + cyclophosphamide + dexamethasone versus bortezomib + lenalidomide + cyclophosphamide + dexamethasone.</ListItem><ListItem>U.S. Intergroup/Intergroupe Francais du Myélome 
trial (IFM): Lenalidomide + bortezomib + dexamethasone for three cycles; responders are then randomly assigned  to five more cycles of  lenalidomide + bortezomib + dexamethasone or high-dose melphalan + stem cell transplantation.</ListItem><ListItem><ProtocolRef href="CDR0000583984" nct_id="NCT00602641">ECOG-E1A06</ProtocolRef> (NCT00602641): Thalidomide + melphalan + prednisone versus lenalidomide + melphalan + prednisone.</ListItem></ItemizedList><Para id="_169"><Strong>Options for combination regimens:</Strong></Para><OrderedList id="_229" Style="Arabic" Compact="No"><ListItem>Bortezomib + dexamethasone (as demonstrated in ECOG-E1A05).<Reference refidx="82"/><Reference refidx="83"/></ListItem><ListItem>Lenalidomide + dexamethasone (as demonstrated in SWOG-S0777).<Reference refidx="11"/><Reference refidx="22"/><Reference refidx="23"/></ListItem><ListItem>Bortezomib + lenalidomide + dexamethasone (as demonstrated in ECOG-E1A05, SWOG-S0777, EVOLUTION trial, and the U.S. Intergroup/IFM trial).<Reference refidx="82"/><Reference refidx="83"/><Reference refidx="84"/></ListItem><ListItem>Bortezomib + cyclophosphamide + dexamethasone (as demonstrated in the EVOLUTION trial).<Reference refidx="85"/><Reference refidx="86"/></ListItem><ListItem>Bortezomib + lenalidomide + cyclophosphamide + dexamethasone (as demonstrated in the EVOLUTION trial).<Reference refidx="87"/></ListItem><ListItem>Carfilzomib + cyclophosphamide + dexamethasone.<Reference refidx="65"/></ListItem><ListItem>Carfilzomib + lenalidomide + dexamethasone.<Reference refidx="66"/></ListItem><ListItem>Bortezomib + melphalan + prednisone.<Reference refidx="51"/></ListItem><ListItem>Bortezomib + liposomal doxorubicin +/- dexamethasone.<Reference refidx="54"/><Reference refidx="88"/></ListItem><ListItem>Bortezomib + bendamustine + dexamethasone.<Reference refidx="89"/> </ListItem><ListItem>Melphalan + prednisone + thalidomide.<Reference refidx="37"/><Reference refidx="45"/></ListItem><ListItem>Melphalan + prednisone.<Reference refidx="37"/><Reference refidx="45"/></ListItem></OrderedList></SummarySection></SummarySection><SummarySection id="_171"><Title>Consolidation Chemotherapy</Title><SummarySection id="_172"><Title>High-dose chemotherapy:  Autologous bone marrow or peripheral stem cell transplantation</Title><Para id="_173">Evidence (high-dose chemotherapy:  autologous bone marrow or peripheral stem cell transplantation):</Para><Para id="_174">The failure of conventional therapy to cure the disease has led
investigators to test the effectiveness of much higher doses of drugs such as
melphalan.  The development of techniques for harvesting hemopoietic stem
cells, from marrow aspirates or the peripheral blood of the patient, and
infusing these cells to promote hemopoietic recovery made it possible for
investigators to test very large doses of chemotherapy.</Para><Para id="_175">Based on the experience of treating
thousands of patients  in this way, it is possible to draw a few
conclusions, including the following:</Para><ItemizedList id="_176" Style="bullet" Compact="No"><ListItem>The risk of early death caused by  treatment-related toxic effects has been
reduced to less than 3% in highly selected populations.<Reference refidx="90"/></ListItem><ListItem>Chemotherapy patients can now be treated as outpatients.</ListItem><ListItem>Extensive prior chemotherapy, especially with alkylating agents,
compromises marrow hemopoiesis and may make the harvesting of adequate numbers
of hemopoietic stem cells impossible.<Reference refidx="10"/></ListItem><ListItem>Younger patients in good health tolerate high-dose therapy better than
patients with a poor performance status.<Reference refidx="91"/><Reference refidx="92"/><Reference refidx="93"/></ListItem><ListItem>Upon review of eight updated trials encompassing more than 3,100 patients, at 10 years' follow-up, there was a 10% to 35% event-free survival (EFS) rate and a 20% to 50% OS rate.<Reference refidx="94"/> New monoclonal gammopathies of an isotype (heavy and/or light chain) distinct from the original clone can emerge in long-term follow-up.<Reference refidx="95"/></ListItem></ItemizedList></SummarySection><SummarySection id="_177"><Title>Single autologous bone marrow or peripheral stem cell transplantation</Title><Para id="_178">Evidence (single autologous bone marrow or peripheral stem cell transplantation):</Para><Para id="_179">While some prospective randomized trials showed improved survival for patients who received autologous peripheral stem cell or bone marrow transplantation after induction chemotherapy versus chemotherapy alone,<Reference refidx="5"/><Reference refidx="96"/><Reference refidx="97"/><Reference refidx="98"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  other trials have not shown any survival advantage.<Reference refidx="99"/><Reference refidx="100"/><Reference refidx="101"/><Reference refidx="102"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] </Para><Para id="_180">Two meta-analyses of almost 3,000 patients showed no survival advantage.<Reference refidx="103"/><Reference refidx="104"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</Para><Para id="_181">Even the trials suggesting improved survival showed no signs of a slowing in the relapse rate or a plateau to suggest that any of these patients had been cured.<Reference refidx="5"/><Reference refidx="96"/><Reference refidx="97"/><Reference refidx="98"/><Reference refidx="105"/> The role of ASCT has also been questioned with the advent of novel induction therapies with high complete-remission rates.<Reference refidx="106"/><Reference refidx="107"/></Para></SummarySection><SummarySection id="_182"><Title>Tandem autologous bone marrow or peripheral stem cell transplantation</Title><Para id="_183">Another approach to high-dose therapy has been the use of two sequential episodes
of high-dose therapy with stem cell support (tandem transplants).<Reference refidx="108"/><Reference refidx="109"/><Reference refidx="110"/><Reference refidx="111"/><Reference refidx="112"/></Para><Para id="_184">Evidence (tandem autologous bone marrow or peripheral stem cell transplantation):</Para><OrderedList id="_185" Style="Arabic" Compact="No"><ListItem>A meta-analysis of six randomized clinical trials enrolling 1,803 patients compared single autologous hematopoietic cell transplantation  with tandem autologous hematopoietic cell transplantation.<ItemizedList id="_186" Style="bullet"><ListItem>There was no difference in OS (HR, 0.94; 95% CI, 0.77–1.14) or in EFS (HR, 0.86; 95% CI, 0.70–1.05).<Reference refidx="113"/>[<LOERef href="CDR0000659430">Level of evidence: 1A</LOERef>]</ListItem></ItemizedList></ListItem><ListItem>In a trial of 194 previously untreated patients aged 50 to 70 years, the patients were randomly assigned to either conventional oral melphalan and prednisone or VAD for two cycles followed by two sequential episodes of high-dose therapy (melphalan 100 mg/m<Superscript>2</Superscript>) with stem cell support.<Reference refidx="98"/><ItemizedList id="_187" Style="bullet"><ListItem>With a median follow-up of more than 3 years, the double transplant group had superior EFS (37% vs. 16% at 3 years, <Emphasis>P</Emphasis> &lt; .001) and OS (77% vs. 62%, <Emphasis>P</Emphasis> &lt; .001).<Reference refidx="98"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</ListItem></ItemizedList></ListItem><ListItem>Five different groups have compared two tandem autologous transplants with one autologous transplant followed by a reduced-intensity conditioning allograft from an HLA-identical sibling; treatment assignment was based on the presence or absence of an HLA-identical sibling. The results have been discordant for survival in these nonrandomized trials.<ItemizedList id="_188" Style="bullet" Compact="No"><ListItem>One study showed a survival advantage for the two tandem autologous transplants.<Reference refidx="114"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>]</ListItem><ListItem>Two studies showed a survival advantage for the autologous transplant followed by an allogeneic transplant.<Reference refidx="115"/><Reference refidx="116"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>]</ListItem><ListItem>Two studies showed no difference in OS.<Reference refidx="117"/><Reference refidx="118"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>]</ListItem></ItemizedList></ListItem><ListItem>A trial of 195 patients younger than   60 years with newly diagnosed myeloma randomly compared two tandem transplants with a single autologous stem cell transplant followed by 6 months of maintenance therapy with thalidomide.<ItemizedList id="_189" Style="bullet"><ListItem>With a median follow-up of 33 months, the thalidomide maintenance arm showed a benefit in PFS (85% vs. 57% at 3 years, <Emphasis>P</Emphasis> = .02) and OS (85% vs. 65% at 3 years, <Emphasis>P</Emphasis> = .04).<Reference refidx="119"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</ListItem></ItemizedList></ListItem><ListItem>Six clinical trials compared the outcomes of patients receiving tandem autologous transplant to those of patients receiving a reduced-intensity allogeneic SCT after autologous transplant.  Patients were assigned to the latter treatments based on the availability of an HLA-matched donor.  Two meta-analyses of these data showed that although the complete remission rate was higher in patients undergoing reduced-intensity allogeneic SCT, OS was comparable because of an increased incidence of nonrelapse mortality with allogeneic transplant.<Reference refidx="120"/><Reference refidx="121"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</ListItem></OrderedList><Para id="_405">A Cochrane review of 14 controlled studies found none of the trials helpful for contemporary treatment decisions regarding single versus tandem transplants.<Reference refidx="122"/> None of the trials employed bortezomib or lenalidomide, and the sharp decrease in compliance with a second transplant complicated sample-size calculations for sufficient statistical power.</Para></SummarySection><SummarySection id="_193"><Title>High-dose chemotherapy:  Allogeneic bone marrow or peripheral stem cell transplantation</Title><Para id="_194">Evidence (high-dose chemotherapy:  allogeneic bone marrow or peripheral stem cell transplantation):</Para><Para id="_361">Many patients are not young enough or healthy enough to
undergo these intensive approaches.  A definite graft-versus-myeloma effect has
been demonstrated, including regression of myeloma relapses following the
infusion of donor lymphocytes.<Reference refidx="123"/></Para><Para id="_196">Favorable prognostic features included the following:</Para><ItemizedList id="_197" Style="bullet"><ListItem>Low tumor burden.</ListItem><ListItem>Responsive disease before transplant.</ListItem><ListItem>Application of transplantation after
first-line therapy.</ListItem></ItemizedList><Para id="_199">Myeloablative allogeneic stem cell transplantation has significant toxic effects (15%–40% mortality), but the possibility of a potent and
possibly curative graft-versus-myeloma effect  in a minority of patients may offset the high transplant-related mortality.<Reference refidx="123"/><Reference refidx="124"/><Reference refidx="125"/> In one anecdotal series of 60 patients who underwent ASCT, six of the patients relapsed between 6 and 12 years, suggesting that late relapses still occur with this type of consolidation.<Reference refidx="126"/></Para><Para id="_200"> The lower transplant-related mortality from nonmyeloablative approaches has been accompanied by a greater risk of relapse.<Reference refidx="125"/> Since the introduction of lenalidomide and bortezomib, a trial exploring donor versus no donor comparison of ASCT) versus autologous SCT and nonmyeloablative allogeneic SCT in 260 untreated patients showed no difference in PFS or OS.<Reference refidx="127"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>] This result contrasted with two older trials (before introduction of lenalidomide and bortezomib), which suggested improvement of PFS and OS with a sibling donor.<Reference refidx="116"/><Reference refidx="128"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>] Given the lack of evidence so far that the high-risk patients benefit from allogeneic stem cell transplantation in this era of novel new agents, it remains debatable whether ASCT should be offered in the first-line setting outside the context of a clinical trial.<Reference refidx="125"/><Reference refidx="129"/></Para><Para id="_446">	Six clinical trials compared the outcomes of patients receiving tandem autologous transplant to those of patients receiving a reduced-intensity allogeneic SCT after autologous transplant.  Patients were assigned to the latter treatments based on the availability of an HLA-matched donor.  Two meta-analyses of these data showed that although the complete remission rate was higher in patients undergoing reduced-intensity allogeneic SCT, OS was comparable because of an increased incidence of nonrelapse mortality with allogeneic transplant.<Reference refidx="120"/><Reference refidx="121"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</Para></SummarySection></SummarySection><SummarySection id="_201"><Title>Maintenance Therapy </Title><Para id="_202">Myeloma patients who respond to treatment show a progressive fall in the
M protein until a plateau is reached; subsequent treatment with conventional
doses does not result in any further improvement.  This has led investigators
to question how long treatment should be continued. No clinical trial has directly compared a consolidation approach with a maintenance approach to assess which is better in prolonging remission and, ultimately, survival.<Reference refidx="130"/> Most clinical trials employ one or both.  Maintenance trials with glucocorticosteroids <Reference refidx="21"/><Reference refidx="131"/> and with interferon <Reference refidx="132"/> showed very minor improvements in remission duration and survival but with toxicities that outweighed the benefits.  The efficacy and tolerability of thalidomide, lenalidomide, and bortezomib in the induction and relapse settings has made these agents attractive options in maintenance trials.<Reference refidx="130"/></Para><SummarySection id="_406"><Title>Thalidomide maintenance therapy</Title><Para id="_407">After ASCT, six randomized, prospective trials showed benefit in PFS for maintenance thalidomide (30–36 months vs. 20–26 months), but only three showed benefit in OS (11–19 months in median OS).<Reference refidx="36"/><Reference refidx="43"/><Reference refidx="133"/><Reference refidx="134"/><Reference refidx="135"/><Reference refidx="136"/> No survival benefit could be consistently seen for thalidomide maintenance after induction chemotherapy alone; interpretation of some trials was confounded by thalidomide use during induction.<Reference refidx="37"/><Reference refidx="135"/><Reference refidx="137"/><Reference refidx="138"/><Reference refidx="139"/><Reference refidx="140"/><Reference refidx="141"/> Several trials suggested particularly poor outcomes using thalidomide for patients with poor-risk cytogenetics.<Reference refidx="43"/><Reference refidx="135"/> The lowest active dose for thalidomide is 50 mg daily with a duration of at least 1 year.</Para></SummarySection><SummarySection id="_408"><Title>Lenalidomide maintenance therapy</Title><Para id="_409">After ASCT, three randomized, prospective trials showed benefit in median EFS or PFS (40–43 months vs. 21–27 months),<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/> one with OS benefit (at a median follow-up of 34 months, 85% vs. 77%;  <Emphasis>P</Emphasis> = .03).<Reference refidx="3"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  For elderly patients not eligible for transplantation, a randomized, prospective trial of lenalidomide maintenance after induction with melphalan and prednisone or melphalan, prednisone, and lenalidomide showed a 66% reduction in the rate of progression (HR, 0.34; <Emphasis>P</Emphasis> &lt; .001), which translated to an EFS of 31 months versus 14 months in favor of maintenance lenalidomide.<Reference refidx="6"/>[<LOERef href="CDR0000335128">Level of evidence: 1iiDi</LOERef>] All three trials showed an increase in myelodysplasia or acute leukemia from 3% to 7%, consistent with other studies of lenalidomide.  Doses of 5 mg to 15 mg a day have been utilized either continuously or with 1 week off every month.</Para></SummarySection><SummarySection id="_410"><Title>Bortezomib maintenance therapy</Title><Para id="_411">For 178 elderly, untreated patients with an induction combination regimen including bortezomib, maintenance using bortezomib plus thalidomide versus bortezomib plus prednisone was not significantly different in PFS or OS, but both resulted in median PFS of 32 to 39 months and a 5-year OS over 50%.<Reference refidx="7"/>[<LOERef href="CDR0000587983">Level of evidence: 1iiDiv</LOERef>] </Para><Para id="_412">In 511 previously untreated patients not eligible for transplant and aged  65 years or older, a randomized comparison of bortezomib plus melphalan plus prednisone plus thalidomide plus subsequent maintenance using bortezomib plus thalidomide versus bortezomib plus melphalan plus prednisone (with no maintenance) showed superiority of the arm with thalidomide and bortezomib during induction and maintenance. </Para><Para id="_413">With a median follow-up of 47 months, 3-year PFS was 55% versus 33% (<Emphasis>P</Emphasis> &lt; .01) and 5-year OS was 59% versus 46% (<Emphasis>P</Emphasis> = .04).<Reference refidx="8"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] Because of trial design, it is unclear whether the improved results were caused by  the addition of thalidomide during the induction or by the use of maintenance therapy with bortezomib and thalidomide.</Para></SummarySection></SummarySection><SummarySection id="_300"><Title>Management of lytic bone lesions with bisphosphonates</Title><SummarySection id="_301"><Title>Bisphosphonate therapy</Title><Para id="_302">Evidence (bisphosphonate therapy):</Para><OrderedList id="_303" Style="Arabic" Compact="No"><ListItem>A randomized, double-blind study of patients with stage III myeloma showed that
monthly intravenous pamidronate significantly reduced pathologic fractures,
bone pain, spinal cord compression, and the need for bone radiation therapy (38% skeletal-related events were reported in the treatment group vs. 51% in the placebo
group after 21 months of therapy, <Emphasis>P </Emphasis>= .015).<Reference refidx="142"/>[<LOERef href="CDR0000335124">Level of evidence: 1iDiii</LOERef>] (Refer to the PDQ summary on <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef> for more information on bisphosphonate therapy.)</ListItem><ListItem>A double-blind, randomized, controlled trial with 504 patients with newly diagnosed multiple myeloma compared 30 mg of pamidronate to 90 mg of pamidronate and found  there was no difference in skeletal-related events, but there was less osteonecrosis (2 events vs. 8 events) seen in the low-dose group.<Reference refidx="143"/>[<LOERef href="CDR0000587981">Level of evidence: 1iDiv</LOERef>]</ListItem><ListItem>A randomized comparison of pamidronate versus zoledronic acid in 518 patients with multiple myeloma showed equivalent efficacy in regard to skeletal-related complications (both were given for 2 years).<Reference refidx="144"/>[<LOERef href="CDR0000335124">Level of evidence: 1iDiii</LOERef>]  </ListItem><ListItem>A randomized, prospective trial of 1,970 patients compared intravenous zoledronate versus oral clodronate in newly diagnosed patients receiving induction chemotherapy with or without consolidation.<Reference refidx="145"/> With a median follow-up of 3.7 years, zoledronate improved median OS from 44.5 months  to 50.0 months (HR, 0.84; CI, 0.74–0.96, <Emphasis>P</Emphasis> = .0118).<Reference refidx="145"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] In this trial, both bisphosphonates were continued until time of relapse.  As expected, skeletal-related events were also reduced in the zoledronate group (27% vs. 35%; <Emphasis>P</Emphasis> = .004).<Reference refidx="146"/><Reference refidx="147"/></ListItem><ListItem>The improvement of median OS with zoledronate was confirmed in a Cochrane network meta-analysis.<Reference refidx="148"/>[<LOERef href="CDR0000659430">Level of evidence: 1A</LOERef>]</ListItem><ListItem> Bisphosphonates are associated with infrequent long-term complications (in 3%–5% of patients), including osteonecrosis of the jaw and avascular necrosis of the hip.<Reference refidx="149"/><Reference refidx="150"/> (Refer to the PDQ summary on <SummaryRef href="CDR0000062870" url="/about-cancer/treatment/side-effects/mouth-throat/oral-complications-hp-pdq">Oral Complications of Chemotherapy and Head/Neck Radiation</SummaryRef> for more information on osteonecrosis of the jaw.) These side effects must be balanced against the potential benefits of bisphosphonates when bone metastases are evident.<Reference refidx="151"/> The optimal use and duration of bisphosphonates for bony involvement in myeloma have not been studied.  Bisphosphonates are usually given intravenously on a monthly basis for 2 years and then extended at the same schedule or at a reduced schedule (i.e., once every 3–4 months), if there is evidence of active myeloma bone disease.<Reference refidx="88"/><Reference refidx="152"/> The aforementioned randomized trial,<Reference refidx="146"/> which showed OS advantage, continued bisphosphonates monthly until time of relapse.</ListItem></OrderedList></SummarySection><SummarySection id="_304"><Title>Radiation therapy for bone lesions</Title><Para id="_305">Lytic lesions of the spine should be radiated if any of the following are true:</Para><OrderedList id="_306" Style="Arabic" Compact="No"><ListItem>If they are associated with an
extramedullary (paraspinal) plasmacytoma.</ListItem><ListItem>If  a painful destruction of a
vertebral body occurred.</ListItem><ListItem>If computed tomography or MRI scans present evidence of spinal
cord compression.<Reference refidx="153"/></ListItem></OrderedList><Para id="_307">Back pain caused by osteoporosis and small compression fractures of the
vertebrae responds best to chemotherapy.   (Refer to the PDQ summary on <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef> for more information on back pain.)</Para><Para id="_308">Extensive radiation of the spine or
long bones for diffuse osteoporosis may lead to prolonged suppression of
hemopoiesis and is rarely indicated.<Reference refidx="154"/></Para><Para id="_309">Bisphosphonates are useful for
slowing or reversing the osteopenia that is common in myeloma patients.<Reference refidx="142"/></Para></SummarySection></SummarySection><SummarySection id="_TrialSearch_107_sid_9"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_107_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=42947&amp;tt=1&amp;format=2&amp;cn=1">multiple myeloma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_107_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="19020545">Dispenzieri A, Kyle R, Merlini G, et al.: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23 (2): 215-24, 2009.</Citation><Citation idx="2" PMID="19541364">Raab MS, Podar K, Breitkreutz I, et al.: Multiple myeloma. Lancet 374 (9686): 324-39, 2009.</Citation><Citation idx="3" PMID="22571201">McCarthy PL, Owzar K, Hofmeister CC, et al.: Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366 (19): 1770-81, 2012.</Citation><Citation idx="4" PMID="22571202">Attal M, Lauwers-Cances V, Marit G, et al.: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366 (19): 1782-91, 2012.</Citation><Citation idx="5" PMID="25184862">Palumbo A, Cavallo F, Gay F, et al.: Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371 (10): 895-905, 2014.</Citation><Citation idx="6" PMID="22571200">Palumbo A, Hajek R, Delforge M, et al.: Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366 (19): 1759-69, 2012.</Citation><Citation idx="7" PMID="22889759">Mateos MV, Oriol A, Martínez-López J, et al.: Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120 (13): 2581-8, 2012.</Citation><Citation idx="8">Palumbo A, Bringhen S, Rossi D, et al.: Overall survival benefit for bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in newly diagnosed multiple myeloma patients. [Abstract] Blood  120 (21): A-200, 2012.</Citation><Citation idx="9" PMID="19005483">Palumbo A, Rajkumar SV: Treatment of newly diagnosed myeloma. Leukemia 23 (3): 449-56, 2009.</Citation><Citation idx="10" PMID="9332333">Goldschmidt H, Hegenbart U, Wallmeier M, et al.: Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 98 (3): 736-44, 1997.</Citation><Citation idx="11" PMID="19853510">Rajkumar SV, Jacobus S, Callander NS, et al.: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11 (1): 29-37, 2010.</Citation><Citation idx="12" PMID="20368561">Mateos MV, Richardson PG, Schlag R, et al.: Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28 (13): 2259-66, 2010.</Citation><Citation idx="13" PMID="17690257">Richardson PG, Sonneveld P, Schuster M, et al.: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110 (10): 3557-60, 2007.</Citation><Citation idx="14" PMID="16754936">Richardson PG, Briemberg H, Jagannath S, et al.: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24 (19): 3113-20, 2006.</Citation><Citation idx="15" PMID="18200040">San-Miguel JF, Richardson PG, Sonneveld P, et al.: Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 22 (4): 842-9, 2008.</Citation><Citation idx="16" PMID="20026810">Bladé J, Dimopoulos M, Rosiñol L, et al.: Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 28 (4): 690-7, 2010.</Citation><Citation idx="17" PMID="19955246">Kumar SK, Mikhael JR, Buadi FK, et al.: Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 84 (12): 1095-110, 2009.</Citation><Citation idx="18" PMID="1498331" MedlineID="92360866">Alexanian R, Dimopoulos MA, Delasalle K, et al.: Primary dexamethasone treatment of multiple myeloma. Blood 80 (4): 887-90, 1992.</Citation><Citation idx="19" PMID="15286691">Kumar S, Lacy MQ, Dispenzieri A, et al.: Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 34 (6): 485-90, 2004.</Citation><Citation idx="20" PMID="16174762">Facon T, Mary JY, Pégourie B, et al.: Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107 (4): 1292-8, 2006.</Citation><Citation idx="21" PMID="17233817">Shustik C, Belch A, Robinson S, et al.: A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 136 (2): 203-11, 2007.</Citation><Citation idx="22" PMID="18032762">Dimopoulos M, Spencer A, Attal M, et al.: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (21): 2123-32, 2007.</Citation><Citation idx="23" PMID="18032763">Weber DM, Chen C, Niesvizky R, et al.: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 (21): 2133-42, 2007.</Citation><Citation idx="24" PMID="25184863">Benboubker L, Dimopoulos MA, Dispenzieri A, et al.: Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371 (10): 906-17, 2014.</Citation><Citation idx="25" PMID="19901114">Zangari M, Tricot G, Polavaram L, et al.: Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 28 (1): 132-5, 2010.</Citation><Citation idx="26" PMID="21835953">Larocca A, Cavallo F, Bringhen S, et al.: Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119 (4): 933-9; quiz 1093, 2012.</Citation><Citation idx="27" PMID="22323483">Dimopoulos MA, Richardson PG, Brandenburg N, et al.: A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 119 (12): 2764-7, 2012.</Citation><Citation idx="28" PMID="20192988">Dimopoulos MA, Christoulas D, Roussou M, et al.: Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 85 (1): 1-5, 2010.</Citation><Citation idx="29" PMID="23299315">Rossi A, Mark T, Jayabalan D, et al.: BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood 121 (11): 1982-5, 2013.</Citation><Citation idx="30" PMID="21690557">Lacy MQ, Allred JB, Gertz MA, et al.: Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 118 (11): 2970-5, 2011.</Citation><Citation idx="31" PMID="23319574">Leleu X, Attal M, Arnulf B, et al.: Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood 121 (11): 1968-75, 2013.</Citation><Citation idx="32" PMID="23243282">Richardson PG, Siegel D, Baz R, et al.: Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121 (11): 1961-7, 2013.</Citation><Citation idx="33" PMID="24007748">San Miguel J, Weisel K, Moreau P, et al.: Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14 (11): 1055-66, 2013.</Citation><Citation idx="34" PMID="23974193">Lacy MQ, McCurdy AR: Pomalidomide. Blood 122 (14): 2305-9, 2013.</Citation><Citation idx="35" PMID="18362366">Rajkumar SV, Rosiñol L, Hussein M, et al.: Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26 (13): 2171-7, 2008.</Citation><Citation idx="36" PMID="16525139">Barlogie B, Tricot G, Anaissie E, et al.: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354 (10): 1021-30, 2006.</Citation><Citation idx="37" PMID="18505783">Palumbo A, Bringhen S, Liberati AM, et al.: Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112 (8): 3107-14, 2008.</Citation><Citation idx="38">Goldschmidt H, Sonneveld P, Breitkreuz I, et al.: HOVON 50/GMMG-HD3-trial: phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years. [Abstract] Blood  106 (11): A-424, 2005.</Citation><Citation idx="39">Waage A, Gimsing P, Juliusson G, et al.: Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. [Abstract] Blood  110 (11): A-78, 2007.</Citation><Citation idx="40" PMID="18955563">Ludwig H, Hajek R, Tóthová E, et al.: Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113 (15): 3435-42, 2009.</Citation><Citation idx="41" PMID="19451428">Hulin C, Facon T, Rodon P, et al.: Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27 (22): 3664-70, 2009.</Citation><Citation idx="42" PMID="19720903">Cavo M, Di Raimondo F, Zamagni E, et al.: Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol 27 (30): 5001-7, 2009.</Citation><Citation idx="43" PMID="19880501">Lokhorst HM, van der Holt B, Zweegman S, et al.: A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115 (6): 1113-20, 2010.</Citation><Citation idx="44" PMID="21663513">Sacchi S, Marcheselli R, Lazzaro A, et al.: A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. Leuk Lymphoma 52 (10): 1942-8, 2011.</Citation><Citation idx="45" PMID="17920916">Facon T, Mary JY, Hulin C, et al.: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370 (9594): 1209-18, 2007.</Citation><Citation idx="46" PMID="18245666">Palumbo A, Facon T, Sonneveld P, et al.: Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111 (8): 3968-77, 2008.</Citation><Citation idx="47" PMID="12506164" MedlineID="22393551">Weber D, Rankin K, Gavino M, et al.: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21 (1): 16-9, 2003.</Citation><Citation idx="48" PMID="16342649">Baz R, Li L, Kottke-Marchant K, et al.: The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80 (12): 1568-74, 2005.</Citation><Citation idx="49" PMID="21282540">Palumbo A, Cavo M, Bringhen S, et al.: Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29 (8): 986-93, 2011.</Citation><Citation idx="50" PMID="20932799">Delforge M, Bladé J, Dimopoulos MA, et al.: Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 11 (11): 1086-95, 2010.</Citation><Citation idx="51" PMID="23233713">San Miguel JF, Schlag R, Khuageva NK, et al.: Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31 (4): 448-55, 2013.</Citation><Citation idx="52" PMID="19170677">Richardson PG, Sonneveld P, Schuster MW, et al.: Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144 (6): 895-903, 2009.</Citation><Citation idx="53" PMID="20874823">Dimopoulos MA, Mateos MV, Richardson PG, et al.: Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 86 (1): 23-31, 2011.</Citation><Citation idx="54" PMID="17679727">Orlowski RZ, Nagler A, Sonneveld P, et al.: Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25 (25): 3892-901, 2007.</Citation><Citation idx="55" PMID="22498745">Cavo M, Pantani L, Petrucci MT, et al.: Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120 (1): 9-19, 2012.</Citation><Citation idx="56" PMID="22585692">Garderet L, Iacobelli S, Moreau P, et al.: Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 30 (20): 2475-82, 2012.</Citation><Citation idx="57" PMID="24449241">Palumbo A, Bringhen S, Larocca A, et al.: Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 32 (7): 634-40, 2014.</Citation><Citation idx="58" PMID="22802322">Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al.: Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 30 (24): 2946-55, 2012.</Citation><Citation idx="59" PMID="20956629">Dimopoulos MA, Terpos E, Chanan-Khan A, et al.: Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28 (33): 4976-84, 2010.</Citation><Citation idx="60" PMID="20807892">Bringhen S, Larocca A, Rossi D, et al.: Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116 (23): 4745-53, 2010.</Citation><Citation idx="61" PMID="20739218">Mateos MV, Oriol A, Martínez-López J, et al.: Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11 (10): 934-41, 2010.</Citation><Citation idx="62" PMID="21507715">Moreau P, Pylypenko H, Grosicki S, et al.: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12 (5): 431-40, 2011.</Citation><Citation idx="63" PMID="23293914">Petrucci MT, Giraldo P, Corradini P, et al.: A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 160 (5): 649-59, 2013.</Citation><Citation idx="64" PMID="25482145">Stewart AK, Rajkumar SV, Dimopoulos MA, et al.: Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 (2): 142-52, 2015.</Citation><Citation idx="65" PMID="24855212">Bringhen S, Petrucci MT, Larocca A, et al.: Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 124 (1): 63-9, 2014.</Citation><Citation idx="66" PMID="22665938">Jakubowiak AJ, Dytfeld D, Griffith KA, et al.: A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120 (9): 1801-9, 2012.</Citation><Citation idx="67" PMID="24014245">Wang M, Martin T, Bensinger W, et al.: Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122 (18): 3122-8, 2013.</Citation><Citation idx="68" PMID="2301376">Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33 (2): 86-9, 1990.</Citation><Citation idx="69" PMID="10233375" MedlineID="99250515">Segeren CM, Sonneveld P, van der Holt B, et al.: Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 105 (1): 127-30, 1999.</Citation><Citation idx="70" PMID="7841049">Anderson H, Scarffe JH, Ranson M, et al.: VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 71 (2): 326-30, 1995.</Citation><Citation idx="71" PMID="1486035">Browman GP, Belch A, Skillings J, et al.: Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group. Br J Haematol 82 (3): 555-9, 1992.</Citation><Citation idx="72" PMID="12853344">Dimopoulos MA, Pouli A, Zervas K, et al.: Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 14 (7): 1039-44, 2003.</Citation><Citation idx="73" PMID="16404741">Rifkin RM, Gregory SA, Mohrbacher A, et al.: Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer 106 (4): 848-58, 2006.</Citation><Citation idx="74" PMID="9850028" MedlineID="99065280">Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 16 (12): 3832-42, 1998.</Citation><Citation idx="75" PMID="1531068" MedlineID="92121948">Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10 (2): 334-42, 1992.</Citation><Citation idx="76">Bergsagel DE, Stewart AK: Conventional-dose chemotherapy of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, et al.: Myeloma: Biology and Management. 3rd ed. Philadelphia, Pa: WB Saunders Co, 2004, pp 203-17.</Citation><Citation idx="77" PMID="3284974" MedlineID="88214441">Pavlovsky S, Corrado C, Santarelli MT, et al.: An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study. J Clin Oncol 6 (5): 769-75, 1988.</Citation><Citation idx="78" PMID="8501503" MedlineID="93274344">Bladé J, San Miguel JF, Alcalá A, et al.: Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 11 (6): 1165-71, 1993.</Citation><Citation idx="79" PMID="9118039" MedlineID="97258847">Oken MM, Harrington DP, Abramson N, et al.: Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 79 (8): 1561-7, 1997.</Citation><Citation idx="80" PMID="10458241" MedlineID="99385423">Gertz MA, Lacy MQ, Lust JA, et al.: Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 17 (1): 262-7, 1999.</Citation><Citation idx="81" PMID="9827927" MedlineID="99043629">Mineur P, Ménard JF, Le Loët X, et al.: VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). Br J Haematol 103 (2): 512-7, 1998.</Citation><Citation idx="82" PMID="18854289">Fonseca R, Rajkumar SV: Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial. Clin Lymphoma Myeloma 8 (5): 315-7, 2008.</Citation><Citation idx="83" PMID="15958804">Richardson PG, Sonneveld P, Schuster MW, et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (24): 2487-98, 2005.</Citation><Citation idx="84">Richardson P, Lonial S, Jakubowiak A, et al.: Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phaseI/II study. [Abstract] Blood  112 (11): A-92, 2008.</Citation><Citation idx="85" PMID="18645194">Reece DE, Rodriguez GP, Chen C, et al.: Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 26 (29): 4777-83, 2008.</Citation><Citation idx="86">Knop S, Liebisch H, Wandt H, et al.: Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: results of an interim analysis of the German DSMM Xia trial. [Abstract] J Clin Oncol  27 (Suppl 15): A-8516, 2009.</Citation><Citation idx="87" PMID="22107129">Khan ML, Reeder CB, Kumar SK, et al.: A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol 156 (3): 326-33, 2012.</Citation><Citation idx="88" PMID="19738129">Jakubowiak AJ, Kendall T, Al-Zoubi A, et al.: Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 27 (30): 5015-22, 2009.</Citation><Citation idx="89" PMID="24227817">Ludwig H, Kasparu H, Leitgeb C, et al.: Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123 (7): 985-91, 2014.</Citation><Citation idx="90" PMID="12893762">Bladé J, Vesole DH, Gertz Morie: High-dose therapy in multiple myeloma. Blood 102 (10): 3469-70, 2003.</Citation><Citation idx="91" PMID="9864145">Siegel DS, Desikan KR, Mehta J, et al.: Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93 (1): 51-4, 1999.</Citation><Citation idx="92" PMID="11552985">Badros A, Barlogie B, Siegel E, et al.: Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 114 (3): 600-7, 2001.</Citation><Citation idx="93" PMID="16643445">Lenhoff S, Hjorth M, Westin J, et al.: Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 133 (4): 389-96, 2006.</Citation><Citation idx="94" PMID="20085933">Barlogie B, Attal M, Crowley J, et al.: Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 28 (7): 1209-14, 2010.</Citation><Citation idx="95" PMID="21765020">Wadhera RK, Kyle RA, Larson DR, et al.: Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood 118 (11): 2985-7, 2011.</Citation><Citation idx="96" PMID="8649495" MedlineID="96266359">Attal M, Harousseau JL, Stoppa AM, et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 335 (2): 91-7, 1996.</Citation><Citation idx="97" PMID="12736280" MedlineID="22621947">Child JA, Morgan GJ, Davies FE, et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (19): 1875-83, 2003.</Citation><Citation idx="98" PMID="15265788">Palumbo A, Bringhen S, Petrucci MT, et al.: Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104 (10): 3052-7, 2004.</Citation><Citation idx="99" PMID="12456509" MedlineID="22496794">Segeren CM, Sonneveld P, van der Holt B, et al.: Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101 (6): 2144-51, 2003.</Citation><Citation idx="100" PMID="16275936">Fermand JP, Katsahian S, Divine M, et al.: High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23 (36): 9227-33, 2005.</Citation><Citation idx="101" PMID="16105975">Bladé J, Rosiñol L, Sureda A, et al.: High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106 (12): 3755-9, 2005.</Citation><Citation idx="102" PMID="16432076">Barlogie B, Kyle RA, Anderson KC, et al.: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24 (6): 929-36, 2006.</Citation><Citation idx="103" PMID="16010209">Lévy V, Katsahian S, Fermand JP, et al.: A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine (Baltimore) 84 (4): 250-60, 2005.</Citation><Citation idx="104" PMID="17241924">Koreth J, Cutler CS, Djulbegovic B, et al.: High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 13 (2): 183-96, 2007.</Citation><Citation idx="105" PMID="18300230">Pineda-Roman M, Barlogie B, Anaissie E, et al.: High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer 112 (8): 1754-64, 2008.</Citation><Citation idx="106" PMID="19554029">Giralt S, Stadtmauer EA, Harousseau JL, et al.: International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23 (10): 1904-12, 2009.</Citation><Citation idx="107" PMID="19878639">Harousseau JL: Hematopoietic stem cell transplantation in multiple myeloma. J Natl Compr Canc Netw 7 (9): 961-70, 2009.</Citation><Citation idx="108" PMID="16939489">Barlogie B, Tricot GJ, van Rhee F, et al.: Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135 (2): 158-64, 2006.</Citation><Citation idx="109" PMID="16322468">Barlogie B, Tricot G, Rasmussen E, et al.: Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107 (7): 2633-8, 2006.</Citation><Citation idx="110" PMID="16796777">Barlogie B, Zangari M, Bolejack V, et al.: Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. Clin Lymphoma Myeloma 6 (6): 469-74, 2006.</Citation><Citation idx="111" PMID="19064724">Bruno B, Rotta M, Patriarca F, et al.: Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 113 (14): 3375-82, 2009.</Citation><Citation idx="112" PMID="19015394">Rotta M, Storer BE, Sahebi F, et al.: Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 113 (14): 3383-91, 2009.</Citation><Citation idx="113" PMID="19141779">Kumar A, Kharfan-Dabaja MA, Glasmacher A, et al.: Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 101 (2): 100-6, 2009.</Citation><Citation idx="114" PMID="18948589">Moreau P, Garban F, Attal M, et al.: Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 112 (9): 3914-5, 2008.</Citation><Citation idx="115" PMID="17360989">Bruno B, Rotta M, Patriarca F, et al.: A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (11): 1110-20, 2007.</Citation><Citation idx="116" PMID="21730266">Björkstrand B, Iacobelli S, Hegenbart U, et al.: Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 29 (22): 3016-22, 2011.</Citation><Citation idx="117" PMID="18612103">Rosiñol L, Pérez-Simón JA, Sureda A, et al.: A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112 (9): 3591-3, 2008.</Citation><Citation idx="118" PMID="21962393">Krishnan A, Pasquini MC, Logan B, et al.: Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 12 (13): 1195-203, 2011.</Citation><Citation idx="119" PMID="17875806">Abdelkefi A, Ladeb S, Torjman L, et al.: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111 (4): 1805-10, 2008.</Citation><Citation idx="120" PMID="22964593">Armeson KE, Hill EG, Costa LJ: Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 48 (4): 562-7, 2013.</Citation><Citation idx="121" PMID="23289975">Kharfan-Dabaja MA, Hamadani M, Reljic T, et al.: Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 6: 2, 2013.</Citation><Citation idx="122" PMID="23076906">Naumann-Winter F, Greb A, Borchmann P, et al.: First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 10: CD004626, 2012.</Citation><Citation idx="123" PMID="11477436" MedlineID="21369446">Reynolds C, Ratanatharathorn V, Adams P, et al.: Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 27 (8): 801-7, 2001.</Citation><Citation idx="124" PMID="15834435">Arora M, McGlave PB, Burns LJ, et al.: Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Bone Marrow Transplant 35 (12): 1133-40, 2005.</Citation><Citation idx="125" PMID="20697091">Lokhorst H, Einsele H, Vesole D, et al.: International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 28 (29): 4521-30, 2010.</Citation><Citation idx="126" PMID="23151215">Sahebi F, Shen Y, Thomas SH, et al.: Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. Br J Haematol 160 (2): 199-206, 2013.</Citation><Citation idx="127" PMID="22442350">Lokhorst HM, van der Holt B, Cornelissen JJ, et al.: Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 119 (26): 6219-25; quiz 6399, 2012.</Citation><Citation idx="128" PMID="21490341">Giaccone L, Storer B, Patriarca F, et al.: Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 117 (24): 6721-7, 2011.</Citation><Citation idx="129" PMID="22745293">Moreau P: Death of frontline allo-SCT in myeloma. Blood 119 (26): 6178-9, 2012.</Citation><Citation idx="130" PMID="22271445">Ludwig H, Durie BG, McCarthy P, et al.: IMWG consensus on maintenance therapy in multiple myeloma. Blood 119 (13): 3003-15, 2012.</Citation><Citation idx="131" PMID="11964279" MedlineID="21961531">Berenson JR, Crowley JJ, Grogan TM, et al.: Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99 (9): 3163-8, 2002.</Citation><Citation idx="132" PMID="11442498" MedlineID="21335951">The Myeloma Trialists' Collaborative Group: Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113 (4): 1020-34, 2001.</Citation><Citation idx="133" PMID="19273705">Spencer A, Prince HM, Roberts AW, et al.: Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27 (11): 1788-93, 2009.</Citation><Citation idx="134" PMID="16873668">Attal M, Harousseau JL, Leyvraz S, et al.: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108 (10): 3289-94, 2006.</Citation><Citation idx="135" PMID="22021371">Morgan GJ, Gregory WM, Davies FE, et al.: The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119 (1): 7-15, 2012.</Citation><Citation idx="136" PMID="18492953">Barlogie B, Pineda-Roman M, van Rhee F, et al.: Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112 (8): 3115-21, 2008.</Citation><Citation idx="137" PMID="16530576">Palumbo A, Bringhen S, Caravita T, et al.: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (9513): 825-31, 2006.</Citation><Citation idx="138" PMID="20516439">Wijermans P, Schaafsma M, Termorshuizen F, et al.: Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 28 (19): 3160-6, 2010.</Citation><Citation idx="139" PMID="20448107">Waage A, Gimsing P, Fayers P, et al.: Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116 (9): 1405-12, 2010.</Citation><Citation idx="140" PMID="20942865">Beksac M, Haznedar R, Firatli-Tuglular T, et al.: Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 86 (1): 16-22, 2011.</Citation><Citation idx="141" PMID="22579366">Kagoya Y, Nannya Y, Kurokawa M: Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res 36 (8): 1016-21, 2012.</Citation><Citation idx="142" PMID="9469347" MedlineID="98129249">Berenson JR, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16 (2): 593-602, 1998.</Citation><Citation idx="143" PMID="20863761">Gimsing P, Carlson K, Turesson I, et al.: Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol 11 (10): 973-82, 2010.</Citation><Citation idx="144" PMID="14534891">Rosen LS, Gordon D, Kaminski M, et al.: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98 (8): 1735-44, 2003.</Citation><Citation idx="145" PMID="21131037">Morgan GJ, Davies FE, Gregory WM, et al.: First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376 (9757): 1989-99, 2010.</Citation><Citation idx="146" PMID="21771568">Morgan GJ, Child JA, Gregory WM, et al.: Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 12 (8): 743-52, 2011.</Citation><Citation idx="147" PMID="22498739">Morgan GJ, Davies FE, Gregory WM, et al.: Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 119 (23): 5374-83, 2012.</Citation><Citation idx="148" PMID="22592688">Mhaskar R, Redzepovic J, Wheatley K, et al.: Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 5: CD003188, 2012.</Citation><Citation idx="149" PMID="16484704">Badros A, Weikel D, Salama A, et al.: Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (6): 945-52, 2006.</Citation><Citation idx="150" PMID="16901034">Kademani D, Koka S, Lacy MQ, et al.: Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 81 (8): 1100-3, 2006.</Citation><Citation idx="151" PMID="16901028">Lacy MQ, Dispenzieri A, Gertz MA, et al.: Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81 (8): 1047-53, 2006.</Citation><Citation idx="152" PMID="19465418">Terpos E, Sezer O, Croucher PI, et al.: The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20 (8): 1303-17, 2009.</Citation><Citation idx="153" PMID="16413695">Rades D, Hoskin PJ, Stalpers LJ, et al.: Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys 64 (5): 1452-7, 2006.</Citation><Citation idx="154" PMID="9422566" MedlineID="98083029">Catell D, Kogen Z, Donahue B, et al.: Multiple myeloma of an extremity: must the entire bone be treated? Int J Radiat Oncol Biol Phys 40 (1): 117-9, 1998.</Citation></ReferenceSection></SummarySection><SummarySection id="_219"><SectMetaData><SpecificDiagnosis ref="CDR0000041876">refractory multiple myeloma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Refractory Multiple Myeloma</Title><Para id="_220">There are two main types of refractory myeloma patients:  </Para><ItemizedList id="_221" Style="bullet" Compact="No"><ListItem>Primary refractory
patients who never achieve a response and progress while still on induction
chemotherapy.  </ListItem><ListItem>Secondary refractory patients who do respond to induction
chemotherapy but do not respond to treatment after relapse.</ListItem></ItemizedList><Para id="_222">A
subgroup of patients who do not achieve a response to induction chemotherapy have stable disease and enjoy a survival prognosis that
is as good as that for responding patients.<Reference refidx="1"/><Reference refidx="2"/> When the stable nature of the
disease becomes established, these types of patients can discontinue therapy until the
myeloma begins to progress again.  Others with primary refractory myeloma and
progressive disease require a change in therapy. (Refer to the <SummaryRef href="CDR0000062866#_107" url="/types/myeloma/hp/myeloma-treatment-pdq">Treatment for Multiple Myeloma</SummaryRef> section of this summary for more information.)</Para><Para id="_223">The myeloma growth rate, as
measured by the monoclonal (or myeloma) protein-doubling time, for patients who respond to their initial therapy increases progressively with each
subsequent relapse, and remission durations become shorter and shorter.  Marrow
function becomes increasingly compromised as patients develop pancytopenia and
enter a refractory phase; occasionally, the myeloma cells dedifferentiate and
extramedullary plasmacytomas develop.  The myeloma cells may still be sensitive
to chemotherapy, but the regrowth rate during relapse is so rapid that
progressive improvement is not observed.
</Para><SummarySection id="_TrialSearch_219_sid_10"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_219_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=41876&amp;tt=1&amp;format=2&amp;cn=1">refractory multiple myeloma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_219_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="12504655" MedlineID="22393043">Riccardi A, Mora O, Tinelli C, et al.: Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol. Eur J Cancer 39 (1): 31-7, 2003.</Citation><Citation idx="2" PMID="15111617">Durie BG, Jacobson J, Barlogie B, et al.: Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 22 (10): 1857-63, 2004.</Citation></ReferenceSection></SummarySection><SummarySection id="_224"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (05/22/2015)</Title><Para id="_225">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_453"><Strong><SummaryRef href="CDR0000062866#_1" url="/types/myeloma/hp/myeloma-treatment-pdq">General Information About Plasma Cell Neoplasms </SummaryRef></Strong></Para><Para id="_454">Updated <SummaryRef href="CDR0000062866#_5" url="/types/myeloma/hp/myeloma-treatment-pdq">statistics</SummaryRef> with estimated new cases and deaths for 2015 (cited American Cancer Society as reference 1).</Para><Para id="_477">Added  <SummaryRef href="CDR0000062866#_232" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to the list of patient evaluation criteria to state that  bone marrow is also usually sent for cytogenetics and fluorescence <Emphasis>in situ</Emphasis> hybridization testing for genetics markers of high-risk disease; the free light chain (FLC) ratio  of over 100 can predict a greater than  70% progression within 2 years in patients with smoldering myeloma (cited Larsen et al. as reference 10); if clinically warranted, taking needle aspirates of a solitary lytic bone lesion, extramedullary
tumor(s), or enlarged lymph node(s) to determine whether these are
plasmacytomas;  and obtain a spinal magnetic resonance imaging scan (or spinal computed tomography [CT] or positron emission tomography-CT scan depending on availability) if the skeletal survey is negative (cited Horger et al. as reference 11,  Walker et al. as reference 12, and Kyle et al. as reference 13); also revised text to state that the presence of circulating myeloma cells is considered a poor prognostic
factor.</Para><Para id="_478">Cited 2014 Rajkumar et al. as <SummaryRef href="CDR0000062866#_15" url="/types/myeloma/hp/myeloma-treatment-pdq">reference 19</SummaryRef>.</Para><Para id="_479">Added<SummaryRef href="CDR0000062866#_18" url="/types/myeloma/hp/myeloma-treatment-pdq"> text</SummaryRef> to state that patients with monoclonal gammopathy of undetermined significance (MGUS) and risk factors for disease progression must be followed carefully because they are more likely to develop myeloma, amyloidosis, lymphoplasmacytic lymphoma, or chronic lymphocytic leukemia   and may
then require therapy.</Para><Para id="_480">Added <SummaryRef href="CDR0000062866#_19" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that the annual risk of progression of MGUS to a lymphoid or plasma cell malignancy ranges from 0.5% to 1.0% in population-based cohorts (cited 2005 Turesson et al. as reference 29). Also added that this risk ranges from 2% to more than 20% in higher-risk patients.</Para><Para id="_481">Added <SummaryRef href="CDR0000062866#_449" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that a Swedish cohort study confirmed the higher-risk factors of abnormal serum-FLC ratio and the high serum–monoclonal protein level; they described the additional risk factor of immunoparesis. Added that the incorporation of gene-expression profiles to better assess risk is also under clinical evaluation (cited Dhodapkar et al. as reference 30).</Para><Para id="_482">Added <SummaryRef href="CDR0000062866#_450" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that monoclonal gammopathies that cause organ damage require immediate therapy with the same strategies applied for the conventional plasma cell dyscrasias.  Also added that  monoclonal gammopathy causing renal dysfunction is referred to as monoclonal gammopathy of renal significance. Added that although the N-terminal pro-brain natriuretic peptide is a very sensitive marker for amyloid involvement in the heart, the low specificity must be noted; these extra tests are included with the M-protein level, FLC levels, and FLC ratio when following patients with MGUS (cited Merlini as reference 31).</Para><Para id="_483"><Strong><SummaryRef href="CDR0000062866#_45" url="/types/myeloma/hp/myeloma-treatment-pdq">Stage Information About Plasma Cell Neoplasms</SummaryRef></Strong></Para><Para id="_484">Added <SummaryRef href="CDR0000062866#_55" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that the otherwise favorable prognosis of hyperploidy is trumped by coexistent adverse cytogenetics (cited Pawlyn et al. as reference 10); revised the Risk Groups for Multiple Myeloma table to show this change  in the Cytogenetic Findings column.</Para><Para id="_485"><Strong><SummaryRef href="CDR0000062866#_57" url="/types/myeloma/hp/myeloma-treatment-pdq">Treatment Option Overview for Plasma Cell Neoplasms </SummaryRef></Strong></Para><Para id="_486">This section was extensively revised.</Para><Para id="_487"><Strong><SummaryRef href="CDR0000062866#_67" url="/types/myeloma/hp/myeloma-treatment-pdq">Treatment for Amyloidosis Associated With Plasma Cell Neoplasms </SummaryRef></Strong></Para><Para id="_488">Cited Reece et al. as <SummaryRef href="CDR0000062866#_73" url="/types/myeloma/hp/myeloma-treatment-pdq">reference 6</SummaryRef>.</Para><Para id="_489"><Strong><SummaryRef href="CDR0000062866#_107" url="/types/myeloma/hp/myeloma-treatment-pdq">Treatment for Multiple Myeloma</SummaryRef></Strong></Para><Para id="_490">Added <SummaryRef href="CDR0000062866#_110" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to the list parameters of initial approaches used to evaluate the patient to include             presence of hypercalcemia and detection of renal dysfunction attributable to the plasma cell dyscrasia.</Para><Para id="_491">Added <SummaryRef href="CDR0000062866#_460" url="/types/myeloma/hp/myeloma-treatment-pdq">Therapeutic Overview</SummaryRef> as a new subsection.</Para><Para id="_492">Added <SummaryRef href="CDR0000062866#_118" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to the list of multiple therapeutic agents that are available for induction therapy, either alone or in combinations, to include histone deacetylase inhibitors and  ponatinib.</Para><Para id="_493">Revised <SummaryRef href="CDR0000062866#_122" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that bortezomib is given subcutaneously and can cause neuropathic toxicities.</Para><Para id="_495">Revised <SummaryRef href="CDR0000062866#_134" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that on the basis of these trials, almost all ongoing clinical trials in the United States and Europe  have implemented the low-dose dexamethasone schedule with or without other therapeutic agents: 40 mg dexamethasone weekly in younger or fit older patients or 20 mg dexamethasone in less-fit older patients.</Para><Para id="_496">Added <SummaryRef href="CDR0000062866#_383" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that a prospective randomized study of 1,623 transplant-ineligible, untreated patients compared lenalidomide and low-dose dexamethasone when given until progression with a 72-week induction regimen versus melphalan plus prednisone plus thalidomide for 72 weeks (cited Benboubker et al. as reference 24); with a median follow-up of 37 months, this trial showed improved overall survival (OS) for patients on the continuous lenalidomide plus dexamethasone (added level of evidence 1iiA); also added that although median progression-free survival (PFS)  was 5 months longer for continuous lenalidomide plus dexamethasone versus 72 weeks of the same regimen, there was no difference in OS (added level of evidence 1iiDiii).</Para><Para id="_497">Added <SummaryRef href="CDR0000062866#_391" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that for 302 patients with relapsed or refractory disease, a pomalidomide and low-dose dexamethasone regimen was compared with high-dose dexamethasone in a randomized prospective trial; after a median follow-up of 10.0 months, the PFS favored the pomalidomide arm by 4.0 to 1.9 months (cited San Miguel et al. as reference 33 and level of evidence 1iiDiii).</Para><Para id="_498">Added <SummaryRef href="CDR0000062866#_451" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that pomalidomide was approved for patients who relapse after two previous regimens, which included bortezomib and lenalidomide; also added that although some myelosuppression and increased risk of thromboembolic events have been noted as with lenalidomide and thalidomide, very little peripheral neuropathy has been noted in comparison with  the other agents (cited Lacy et al. as reference 34).</Para><Para id="_499">Added <SummaryRef href="CDR0000062866#_476" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that late in the disease course, when all other options have failed, thalidomide can be employed, sometimes with durable responses (cited 2008 Palumbo et al. as reference 46). </Para><Para id="_500">Revised <SummaryRef href="CDR0000062866#_394" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that with a median follow-up of 54 months, 3-year PFS was 35% versus 25%, and 5-year OS was 61% versus 51% (cited Palumbo et al. [J Clin Oncol  2014] as reference 57 and level of evidence 1iiA). </Para><Para id="_501">Added <SummaryRef href="CDR0000062866#_394" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that more than 6 months after completion of bortezomib induction therapy, bortezomib can be applied again with a 40% overall response rate according to  one anecdotal phase II trial (cited Petrucci et al. as reference 63 and level of evidence 3iiiDiv).</Para><Para id="_503">Added <SummaryRef href="CDR0000062866#_402" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> with evidence about carfilzomib as a new subsection.</Para><Para id="_504">Added <SummaryRef href="CDR0000062866#_229" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to include three additional options for combination regimens: carfilzomib, cyclophosphamide, and dexamethasone (cited Bringhen et al. as reference 65); carfilzomib, lenalidomide, and dexamethasone (cited Jakubowiak et al. as reference 66); and bortezomib, bendamustine, and dexamethasone (cited Ludwig et al. as reference 89).</Para><Para id="_505">Added Palumbo et al. N Engl J 2014 as <SummaryRef href="CDR0000062866#_179" url="/types/myeloma/hp/myeloma-treatment-pdq">reference 5</SummaryRef>.</Para><Para id="_506"> Added <SummaryRef href="CDR0000062866#_199" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that in one anecdotal series of 60 patients who underwent allogeneic stem cell transplantation (ASCT), six of the patients relapsed between 6 and 12 years, suggesting that late relapses still occur with this type of consolidation (cited Sahebi et al. as reference 126).</Para><Para id="_507">Revised <SummaryRef href="CDR0000062866#_409" url="/types/myeloma/hp/myeloma-treatment-pdq">text</SummaryRef> to state that after ASCT, three randomized, prospective trials showed benefit in median event-free survival or PFS, one with OS benefit.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062866#_AboutThis_1" url="http://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about treatment of plasma cell neoplasms (including multiple myeloma). It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Steven D. Gore, MD (Yale University School of Medicine)</ListItem><ListItem>Mark J. Levis, MD, PhD (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins)</ListItem><ListItem>Eric J. Seifter, MD (Johns Hopkins University)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq">http://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2015-05-22</DateLastModified></Summary>
